| Ident. | Authors (with country if any) | Title |
|---|
| 000108 |
Frances M. Weaver [États-Unis] ; Kevin T. Stroupe [États-Unis] ; LISHAN CAO [États-Unis] ; Robert G. Holloway [États-Unis] ; Barbara G. Vickrey [États-Unis] ; Tanya Simuni [États-Unis] ; Ann Hendricks [États-Unis] ; Dolores Ippolito [États-Unis] | Parkinson's Disease Medication Use and Costs Following Deep Brain Stimulation |
| 000379 |
Lynn Rochester [Royaume-Uni] ; Katherine Baker [Royaume-Uni] ; Alice Nieuwboer [Belgique] ; David Burn [Royaume-Uni] | Targeting Dopa-Sensitive and Dopa-Resistant Gait Dysfunction in Parkinson's Disease: Selective Responses to Internal and External Cues |
| 000620 |
Andreas Kupsch [Allemagne] ; Michele Tagliati [États-Unis] ; Marie Vidailhet [France] ; Tipu Aziz [Royaume-Uni] ; Paul Krack [France] ; Elena Moro [Canada] ; Joachim K. Krauss [Allemagne] | Early Postoperative Management of DBS in Dystonia: Programming, Response to Stimulation, Adverse Events, Medication Changes, Evaluations, and Troubleshooting |
| 000633 |
Alberto J. Espay [États-Unis] ; Joe P. Giuffrida [États-Unis] ; Robert Chen [Canada] ; Megan Payne [États-Unis] ; Filomena Mazzella [Canada] ; Emily Ounn [États-Unis] ; Jennifer E. Vaughan [États-Unis] ; Andrew P. Duker [États-Unis] ; Alok Sahay [États-Unis] ; SANG JIN KIM [Canada] ; Fredy J. Revilla [États-Unis] ; Dustin A. Heldman [États-Unis] | Differential Response of Speed, Amplitude, and Rhythm to Dopaminergic Medications in Parkinson's Disease |
| 000738 |
Domenico Italiano [Italie] ; Marianna Pezzella [Italie] ; Antonietta Coppola [Italie] ; Adriana Magaudda [Italie] ; Edoardo Ferlazzo [Italie] ; Placido Bramanti [Italie] ; Salvatore Striano [Italie] ; Federico Zara [Italie] ; Pasquale Striano [Italie] | A Pilot Open-Label Trial of Zonisamide in Unverricht-Lundborg Disease |
| 000892 |
Keith L. Davis [États-Unis] ; Heather M. Edin [États-Unis] ; Jeffery K. Allen [États-Unis] | Prevalence and Cost of Medication Nonadherence in Parkinson's Disease: Evidence from Administrative Claims Data |
| 000B50 |
Alessandro Rotondo [Italie] ; Domenico Bosco [Italie] ; Massimiliano Plastino [Italie] ; Arturo Consoli [Italie] ; Francesca Bosco [Italie] | Clozapine for Medication-Related Pathological Gambling in Parkinson Disease |
| 000D20 |
Luigi M. Romito [Italie] ; Maria Fiorella Contarino [Italie] ; Nicola Vanacore [Italie] ; Anna Rita Bentivoglio [Italie] ; Massimo Scerrati [Italie] ; Alberto Albanese [Italie] | Replacement of Dopaminergic Medication with Subthalamic Nucleus Stimulation in Parkinson's Disease : Long-Term Observation |
| 000D81 |
Joanne Difrancisco-Donoghue [États-Unis] ; Ahmed Elokda [États-Unis] ; Eric M. Lamberg [États-Unis] ; Nancy Bono [États-Unis] ; William G. Werner [États-Unis] | Norepinephrine and Cardiovascular Responses to Maximal Exercise in Parkinson's Disease On and Off Medication |
| 000E97 |
Elizabeth L. Stegemöller [États-Unis] ; Tanya Simuni [États-Unis] ; Colum Mackinnon [États-Unis] | Effect of Movement Frequency on Repetitive Finger Movements in Patients with Parkinson's Disease |
| 000F91 |
Donald Grosset [Royaume-Uni] ; Angelo Antonini [Italie] ; Margherita Canesi [Italie] ; Gianni Pezzoli [Italie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Karen Shaw [Royaume-Uni] ; Esther Cubo [Espagne] ; Pablo Martinez-Martin [Espagne] ; Olivier Rascol [France] ; Laurence Negre-Pages [France] ; Ana Senard [France] ; Johannes Schwarz [Allemagne] ; Karl Strecker [Allemagne] ; Heinz Reichmann [Allemagne] ; Alexander Storch [Allemagne] ; Matthias Löhle [Allemagne] ; Fabrizio Stocchi [Italie] ; Katherine Grosset [Royaume-Uni] | Adherence to Antiparkinson Medication in a Multicenter European Study |
| 000F93 |
Edward J. Newman [Royaume-Uni] ; Kieran Breen [Royaume-Uni] ; Jim Patterson [Royaume-Uni] ; Donald M. Hadley [Royaume-Uni] ; Katherine A. Grosset [Royaume-Uni] ; Donald G. Grosset [Royaume-Uni] | Accuracy of Parkinson's Disease Diagnosis in 610 General Practice Patients in the West of Scotland |
| 001068 |
Sebastian Paus [Allemagne] ; Anne Grünewald [Allemagne] ; Christine Klein [Allemagne] ; Michael Knapp [Allemagne] ; Alexander Zimprich [Allemagne] ; Bernd Janetzky [Allemagne] ; Jens C. Möller [Allemagne] ; Thomas Klockgether [Allemagne] ; Ullrich Wüllner [Allemagne] | The DRD2 TaqIA Polymorphism and Demand of Dopaminergic Medication in Parkinson's Disease |
| 001114 |
Peter Valkovic [Slovaquie] ; Hana Brozova [République tchèque] ; Kai Bötzel [Allemagne] ; Evzen Ruzicka [République tchèque] ; Jan Benetin [Slovaquie] | Push and Release Test Predicts Better Parkinson Fallers and Nonfallers than the Pull Test : Comparison in OFF and ON Medication States |
| 001128 |
Alison La Pean [États-Unis] ; Neal Jeffries [États-Unis] ; Chelsea Grow [États-Unis] ; Bernard Ravina [États-Unis] ; Nicholas A. Di Prospero [États-Unis] | Predictors of Progression in Patients with Friedreich Ataxia |
| 001196 |
Amit S. Kulkarni [États-Unis] ; Rajesh Balkrishnan [États-Unis] ; Roger T. Anderson [États-Unis] ; Heather M. Edin [États-Unis] ; Jeff Kirsch [Royaume-Uni] ; Mark A. Stacy [États-Unis] | Medication Adherence and Associated Outcomes in Medicare Health Maintenance Organization-Enrolled Older Adults with Parkinson's Disease |
| 001197 |
Nir Giladi [Israël] | Medical Treatment of Freezing of Gait |
| 001275 |
Jennifer G. Goldman [États-Unis] ; Christopher G. Goetz [États-Unis] ; Melanie Brandabur [États-Unis] ; Michelle Sanfilippo [États-Unis] ; Glenn T. Stebbins [États-Unis] | Effects of Dopaminergic Medications on Psychosis and Motor Function in Dementia with Lewy Bodies |
| 001368 |
Christopher G. Goetz [États-Unis] ; WENQING FAN [États-Unis] ; Sue Leurgans [États-Unis] | Antipsychotic Medication Treatment for Mild Hallucinations in Parkinson's Disease : Positive Impact on Long-Term Worsening |
| 001440 |
Ikwunga Wonodi [États-Unis] ; Gloria Reeves [États-Unis] ; Dana Carmichael [États-Unis] ; Ilene Verovsky [États-Unis] ; Matthew T. Avila [États-Unis] ; Amie Elliott [États-Unis] ; L. Elliot Hong [États-Unis] ; Helene M. Adami [États-Unis] ; Gunvant K. Thaker [États-Unis] | Tardive dyskinesia in children treated with atypical antipsychotic medications |
| 001512 |
Francesc Valldeoriola [Espagne] ; Ossama Morsi [Espagne] ; Eduardo Tolosa [Espagne] ; Jordi Rumia [Espagne] ; Maria José Marti [Espagne] ; Pablo Martinez-Martin [Espagne] | Prospective Comparative Study on Cost-Effectiveness of Subthalamic Stimulation and Best Medical Treatment in Advanced Parkinson's Disease |
| 001723 |
Molly M. Sturman [États-Unis] ; David E. Vaillancourt [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Diane K. Sierens [États-Unis] ; Roy A. E. Bakay [États-Unis] ; Daniel M. Corcos [États-Unis] | Deep brain stimulation and medication for parkinsonian tremor during secondary tasks |
| 001877 |
Deborah A. Hall [États-Unis] ; Elizabeth Berry-Kravis [États-Unis] ; Randi J. Hagerman [États-Unis] ; Paul J. Hagerman [États-Unis] ; Cathlin D. Rice [États-Unis] ; Maureen A. Leehey [États-Unis] | Symptomatic treatment in the fragile X-associated tremor/ ataxia syndrome |
| 001881 |
Vicky L. Marshall [Royaume-Uni] ; Jim Patterson [Royaume-Uni] ; Donald M. Hadley [Royaume-Uni] ; Katherine A. Grosset [Royaume-Uni] ; Donald G. Grosset [Royaume-Uni] | Successful antiparkinsonian medication withdrawal in patients with parkinsonism and normal FP-CIT SPECT |
| 001887 |
Lisa M. Shulman [États-Unis] ; Ingrid Pretzer-Aboff [États-Unis] ; Karen E. Anderson [États-Unis] ; Rashida Stevenson [États-Unis] ; Christopher G. Vaughan [États-Unis] ; Ann L. Gruber-Baldini [États-Unis] ; Stephen G. Reich [États-Unis] ; William J. Weiner [États-Unis] | Subjective report versus objective measurement of activities of daily living in parkinson's disease |
| 001B03 |
Angela Deutschl Nder [Allemagne] ; Friedrich Asmus [Allemagne] ; Elena Marelli [Allemagne] ; Thomas Klopstock [Allemagne] ; Thomas Gasser [Allemagne] ; Kai Botzel [Allemagne] | Excellent response to apomorphine in parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication |
| 001B20 |
David E. Vaillancourt [États-Unis] ; Janey Prodoehl [États-Unis] ; Molly M. Sturman [États-Unis] ; Roy A. E. Bakay [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Daniel M. Corcos [États-Unis] | Effects of deep brain stimulation and medication on strength, bradykinesia, and electromyographic patterns of the ankle joint in Parkinson's disease |
| 001C14 |
Nicole Shivitz [États-Unis] ; Mandy Miller Koop [États-Unis] ; Jahan Fahimi [États-Unis] ; Gary Heit [États-Unis] ; Helen M. Bronte-Stewart [États-Unis] | Bilateral subthalamic nucleus deep brain stimulation improves certain aspects of postural control in Parkinson's disease, whereas medication does not |
| 001D03 |
Katherine A. Grosset [Royaume-Uni] ; Ian Bone [Royaume-Uni] ; Donald G. Grosset [Royaume-Uni] | Suboptimal medication adherence in Parkinson's disease |
| 001D35 |
Ana Lisa Taylor Tavares [États-Unis] ; Gregory S. X. E. Jefferis [États-Unis] ; Mandy Koop [États-Unis] ; Bruce C. Hill [États-Unis] ; Trevor Hastie [États-Unis] ; Gary Heit [États-Unis] ; Helen M. Bronte-Stewart [États-Unis] | Quantitative measurements of alternating finger tapping in Parkinson's disease correlate with UPDRS motor disability and reveal the improvement in fine motor control from medication and deep brain stimulation |
| 001D83 |
C. Warren Olanow [États-Unis] ; Joseph Jankovic [États-Unis] | Neuroprotective therapy in Parkinson's disease and motor complications : A search for a pathogenesis-targeted, disease-modifying strategy |
| 001E84 |
J. Carsten Moller [Allemagne] ; Mira Rethfeldt [Allemagne] ; Yvonne Körner [Allemagne] ; Karin Stiasny-Kolster [Allemagne] ; Werner Cassel [Allemagne] ; Charlotte Meindorfner [Allemagne] ; Ida Rissling [Allemagne] ; Hans-Peter Krüger [Allemagne] ; Wolfgang H. Oertel [Allemagne] | Daytime sleep latency in medication-matched parkinsonian patients with and without sudden onset of sleep |
| 001F31 |
Valerie E. Kelly [États-Unis] ; Amy J. Bastian [États-Unis] | Antiparkinson medications improve agonist activation but not antagonist inhibition during sequential reaching movements |
| 002143 |
Fredricka C. Martin [États-Unis] ; ANH THU LE [États-Unis] ; Adrian Handforth [États-Unis] | Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications |
| 002287 |
Francisco Cardoso [Brésil] ; Débora Maia [Brésil] ; Mauro César Q. S. Cunningham [Brésil] ; Guilherme Valenca [Brésil] | Treatment of sydenham chorea with corticosteroids |
| 002289 |
Roy R. Reeves [États-Unis] ; Vincent Liberto [États-Unis] | Treatment of essential blepharospasm with quetiapine |
| 002291 |
Francisco Grandas [Espagne] ; Jaime Kulisevsky [Espagne] | Treatment of Parkinson's disease in Spain |
| 002297 |
John M. Walshe [Royaume-Uni] | The story of penicillamine: A difficult birth |
| 002318 |
Tomoyuki Uchiyama [Japon] ; Ryuji Sakakibara [Japon] ; Takamichi Hattori [Japon] ; Tomonori Yamanishi [Japon] | Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon |
| 002343 |
Prithiva Navan [Royaume-Uni] ; Leslie J. Findley [Royaume-Uni] ; Jim A. R. Jeffs [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter G. Bain [Royaume-Uni] | Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on parkinsonian tremor |
| 002344 |
Yoshikuni Mizuno [Japon] ; Nobuo Yanagisawa [Japon] ; Sadako Kuno [Japon] ; Mitsutoshi Yamamoto [Japon] ; Kazuko Hasegawa [Japon] ; Hideki Origasa [Japon] ; Hisayuki Kowa [Japon] | Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease |
| 002345 |
Charles H. Adler [États-Unis] ; John N. Caviness [États-Unis] ; Joseph G. Hentz [États-Unis] ; Marlene Lind [États-Unis] ; Judy Tiede [États-Unis] | Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease |
| 002352 |
Werner Poewe [Autriche] | Psychosis in Parkinson's disease |
| 002378 |
Silvia Folgar [Argentine] ; Emilia Mabel Gatto [Argentine] ; Gabriela Raina [Argentine] ; Federico Micheli [Argentine] | Parkinsonism as a manifestation of multiple sclerosis |
| 002383 |
Ali Samii [États-Unis] ; Debra D. Dahlen [États-Unis] ; Alexander M. Spence [États-Unis] ; Nicole C. Maronian [États-Unis] ; Eric E. Kraus [États-Unis] ; Vanda A. Lennon [États-Unis] | Paraneoplastic movement disorder in a patient with non-Hodgkin's lymphoma and CRMP-5 autoantibody |
| 002387 |
Claudia Trenkwalder [Allemagne] ; Victor Collado Seidel [Allemagne] ; Jörg Kazenwadel [Suisse] ; Thomas C. Wetter [Allemagne] ; Wolfgang Oertel [Allemagne] ; Roland Selzer [Allemagne] ; Ralf Kohnen [Allemagne] | One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome? |
| 002391 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
| 002406 |
Rajesh Pahwa [États-Unis] ; Kelly E. Lyons [États-Unis] | Mirtazapine in essential tremor: A double-blind, placebo-controlled pilot study |
| 002411 |
Jan Herzog [Allemagne] ; Julia Reiff [Allemagne] ; Paul Krack [Allemagne] ; Karsten Witt [Allemagne] ; Bettina Schrader [Allemagne] ; Dieter Müller [Allemagne] ; Günther Deuschl [Allemagne] | Manic episode with psychotic symptoms induced by subthalamic nucleus stimulation in a patient with Parkinson's disease |
| 002414 |
Hubert H. Fernandez [États-Unis] ; Martha E. Trieschmann [États-Unis] ; Monica A. Burke [États-Unis] ; Carol Jacques [États-Unis] ; Joseph H. Friedman [États-Unis] | Long-term outcome of quetiapine use for psychosis among parkinsonian patients |
| 002419 |
Jau-Shin Lou [États-Unis] ; Greg Kearns [États-Unis] ; Theodore Benice [États-Unis] ; Barry Oken [États-Unis] ; Gary Sexton [États-Unis] ; John Nutt [États-Unis] | Levodopa improves physical fatigue in Parkinson's disease: A double-blind, placebo-controlled, crossover study |
| 002429 |
Birgit Hogl [Autriche] ; Klaus Seppi [Autriche] ; Elisabeth Brandauer [Autriche] ; Susanne Glatzl [Autriche] ; Birgit Frauscher [Autriche] ; Ulrike Niedermüller [Autriche] ; Gregor Wenning [Autriche] ; Werner Poewe [Autriche] | Increased daytime sleepiness in Parkinson's disease: A questionnaire survey |
| 002438 |
Melih Vural [Turquie] ; Sibel Özekmekci [Turquie] ; Hülya Apaydin [Turquie] ; Attila Altinel [Turquie] | High-dose piracetam is effective on cerebellar ataxia in a patient with cerebellar cortical atrophy |
| 002449 |
William G. Ondo [États-Unis] ; Christine Hunter [États-Unis] | Flumazenil, a GABA antagonist, may improve features of Parkinson's Disease |
| 002450 |
Juha-Matti Savola [Finlande] ; Michael Hill [Royaume-Uni] ; Mia Engstrom [Finlande] ; Hannele Merivuori [Finlande] ; Siegfried Wurster [Finlande] ; Steven G. Mcguire [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease |
| 002465 |
Kathy Steece-Collier [États-Unis] ; Timothy J. Collier [États-Unis] ; Paul D. Danielson [États-Unis] ; Roger Kurlan [États-Unis] ; David M. Yurek [États-Unis] ; John R. Jr Sladek [États-Unis] | Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in Parkinsonian rats |
| 002466 |
Ryoichi Hayashi [Japon] ; Takao Hashimoto [Japon] ; Kenji Tako [Japon] | Efficacy of propranolol in hyperthyroid-induced chorea: A case report |
| 002467 |
Marc Ziegler [France] ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France] | Efficacy of Piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study |
| 002469 |
Amy J. Bastian [États-Unis] ; Valerie E. Kelly [États-Unis] ; Joel S. Perlmutter [États-Unis] ; Jonathan W. Mink [États-Unis] | Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease |
| 002472 |
Lance A. Smith [Royaume-Uni] ; Michael J. Jackson ; Matthew J. Hansard ; Eleni Maratos ; Peter Jenner | Effect of pulsatile administration of Levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: Effect of dose, frequency of administration, and brain exposure |
| 002477 |
Prithiva Navan [Royaume-Uni] ; Leslie J. Findley [Royaume-Uni] ; Jim A. R. Jeffs [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter G. Bain [Royaume-Uni] | Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest Tremor and UPDRS part III in Parkinson's disease |
| 002478 |
Francesca Mancini [Italie] ; Roberta Zangaglia [Italie] ; Silvano Cristina [Italie] ; Maria Grazia Sommaruga [Italie] ; Emilia Martignoni [Italie] ; Giuseppe Nappi [Italie] ; Claudio Pacchetti [Italie] | Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of Drooling in parkinsonism |
| 002479 |
Carsten Buhmann [Allemagne] ; Alexandra Bussopulos [Allemagne] ; Matthias Oechsner [Allemagne] | Dopaminergic response in Parkinsonian phenotype of Machado-Joseph Disease |
| 002484 |
Ronald B. Postuma [Canada, États-Unis] ; Yoshiaki Furukawa [Canada] ; Ekaterina Rogaeva [Canada] ; Peter H. St. George-Hyslop [Canada] ; Matt J. Farrer [Canada] ; Anthony E. Lang [Canada] | Dopa-responsive dystonia presenting with prominent isolated bilateral resting leg tremor: Evidence for a role of Parkin? |
| 002500 |
Eduardo Tolosa [Espagne] ; Miguel Coelho [Espagne] ; Marisol Gallardo [Espagne] | DAT imaging in drug-induced and psychogenic parkinsonism |
| 002501 |
David J. Burn [Royaume-Uni] ; Ian G. Mckeith [Royaume-Uni] | Current treatment of Dementia with lewy bodies and Dementia associated with Parkinson's disease |
| 002514 |
Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada] | Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys |
| 002518 |
Cathy Chuang [États-Unis] ; Anne Constantino [États-Unis] ; Casilda Balmaceda [États-Unis] ; David Eidelberg [États-Unis] ; Steven J. Frucht [États-Unis] | Chemotherapy-induced Parkinsonism responsive to levodopa: An underrecognized entity |
| 002519 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications |
| 002524 |
Antje M. Smala [Allemagne] ; E. Annika Spottke [Allemagne] ; Olaf Machat [Allemagne] ; Uwe Siebert [États-Unis] ; Dieter Meyer [Allemagne] ; Rudolf Köhne-Volland [Allemagne] ; Martin Reuther [Allemagne] ; Janeen Duchane [États-Unis] ; Wolfgang H. Oertel [Allemagne] ; Karin B. Berger [Allemagne] ; Richard C. Dodel [Allemagne] | Cabergoline versus levodopa monotherapy: A decision analysis |
| 002528 |
Brad A. Racette [États-Unis] ; Laura Good [États-Unis] ; Sandy Sagitto [États-Unis] ; Joel S. Perlmutter [États-Unis] | Botulinum toxin B reduces sialorrhea in parkinsonism |
| 002532 |
Noël L. W. Keijsers [Pays-Bas] ; Martin W. I. M. Horstink [Pays-Bas] ; Stan C. A. M. Gielen [Pays-Bas] | Automatic assessment of levodopa-induced dyskinesias in daily life by neural networks |
| 002535 |
Isabelle Benatru [France] ; Stéphane Thobois [France] ; Nathalie Andre-Obadia [France] ; Pierre-Marie Gonnaud [France] ; Yara Beaugendre [France] ; Colette Berger [France] ; Michel Gonce [Belgique] ; Emmanuel Broussolle [France] | Atypical propriospinal myoclonus with possible relationship to α interferon therapy |
| 002545 |
Aurélie Funkiewiez [France] ; Claire Ardouin [France] ; Paul Krack [France] ; Valérie Fraix [France] ; Nadège Van Blercom [France] ; JING XIE [France] ; Elena Moro [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] | Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease |
| 002553 |
| Management of Parkinson's disease: an evidence-based review |
| 002556 |
Ergun Y. Uc [États-Unis] ; Gerald A. Dienel [États-Unis] ; Nancy F. Cruz [États-Unis] ; Sami I. Harik [États-Unis] | β-Adrenergics enhance brain extraction of levodopa |
| 002565 |
Padraic J. Grattan-Smith [Australie] ; Ron A. Wevers [Pays-Bas] ; Gerry C. Steenbergen-Spanjers [Pays-Bas] ; Victor S. C. Fung [Australie] ; John Earl [Australie] ; Bridget Wilcken [Australie] | Tyrosine hydroxylase deficiency: Clinical manifestations of catecholamine insufficiency in infancy |
| 002573 |
Manavdeep Grewal [Canada] ; Raed Hawa [Canada] ; Colin Shapiro [Canada] | Treatment of periodic limb movements in sleep with selegiline HCl |
| 002574 |
| Treatment of depression in idiopathic Parkinson's disease |
| 002582 |
Ronald K. B. Pearce [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Tara Banerji [Royaume-Uni] ; Jorgen Scheel-Krüger [Danemark] ; Peter Jenner [Royaume-Uni] | The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets |
| 002585 |
Louis C. Tan [États-Unis] ; Peter H. Protell [États-Unis] ; J. William Langston [États-Unis] ; Daniel M. Togasaki [États-Unis] | The Hyperkinetic Abnormal Movements Scale: A tool for measuring levodopa-induced Abnormal Movements in squirrel monkeys |
| 002589 |
Daniel Tarsy [États-Unis] ; Gerald Indorf [États-Unis] | Tardive tremor due to metoclopramide |
| 002598 |
Robert Schauer [Autriche] ; Markus Singer [Autriche] ; Leopold Saltuari [Autriche] ; Markus Kofler [Autriche] | Suppression of cortical myoclonus by levetiracetam |
| 002600 |
H. Christopher Hyson [Canada] ; Andrew M. Johnson [Canada] ; Mandar S. Jog [Canada] | Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study |
| 002601 |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie [Royaume-Uni] | Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease |
| 002617 |
Brad A. Racette [États-Unis] ; Mikula Stambuk [États-Unis] ; Joel S. Perlmutter [États-Unis] | Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024) |
| 002618 |
Charles H. Adler [États-Unis] ; Stewart A. Factor [États-Unis] ; Mitchell Brin [États-Unis] ; Kapil D. Sethi [États-Unis] | Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia |
| 002620 |
Jörg Müller [Autriche] ; Gregor K. Wenning [Autriche] ; Jörg Wissel [Autriche] ; Angelika Baldauf [Autriche] ; Klaus Seppi [Autriche] ; Christian Brenneis [Autriche] ; Werner Poewe [Autriche] | Riluzole therapy in cervical dystonia |
| 002621 |
Johannes Schiefer [Allemagne] ; G. Bernhard Landwehrmeyer [Allemagne] ; Hans-Gerd Lüesse [Allemagne] ; Arne Sprünken [Allemagne] ; Christiane Puls [Allemagne] ; Anna Milkereit [Allemagne] ; Eva Milkereit [Allemagne] ; Christoph M. Kosinski [Allemagne] | Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease |
| 002622 |
Giorgio Fabiani [Brésil] ; Hélio A. G. Teive [Brésil] ; Francisco M. B. Germiniani [Brésil] ; Daniel S. Sa [Brésil] ; Lineu César Werneck [Brésil] | Reversible Parkinsonian syndrome in systemic and brain vasculitis |
| 002626 |
Lance A. Smith [Royaume-Uni] ; Banu C. Tel [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Rogelio Braceras [Royaume-Uni] ; Céline Bonhomme [France] ; Claire Chezaubernard [France] ; Susanna Del Signore [France] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Repeated administration of Piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: A behavioural and biochemical investigation |
| 002629 |
Padraig O'Suilleabhain [États-Unis] ; Richard B. Jr Dewey [États-Unis] | Randomized trial comparing primidone initiation schedules for treating essential tremor |
| 002630 |
Susan H. Fox [Royaume-Uni] ; Mark Kellett [Royaume-Uni] ; A. Peter Moore [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia |
| 002631 |
Robert A. Hauser [États-Unis] ; Nicholas H. G. Holford [Nouvelle-Zélande] | Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's Disease |
| 002653 |
Christopher G. Goetz [États-Unis] ; Sue Leurgans [États-Unis] ; Rema Raman [États-Unis] | Placebo-associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease |
| 002654 |
William G. Ondo [États-Unis] ; Amit Verma [États-Unis] | Physiological assessment of paroxysmal dystonia secondary to subacute sclerosing panencephalitis |
| 002662 |
Alfredo Berardelli [Italie] ; Antonio Curra [Italie] | Pathophysiology and treatment of cranial dystonia |
| 002664 |
Hélio A. G. Teive [Brésil] ; Francisco M. B. Germiniani [Brésil] ; Lineu César Werneck [Brésil] | Parkinsonian syndrome induced by amlodipine: Case report |
| 002666 |
Giulio Cicarelli [Italie] ; Maria Teresa Pellecchia [Italie] ; Giuseppe De Michele [Italie] ; Gilberto Pizzolato [Italie] ; Paolo Barone [Italie] | Paradoxical response to apomorphine in a case of atypical parkinsonism |
| 002671 |
Ruth Djaldetti [Israël] ; Rivkah Inzelberg [Israël] ; Nir Giladi [Israël] ; Amos D. Korczyn [Israël] ; Yehudit Peretz-Aharon [Israël] ; Martin J. Rahey [Israël] ; Yuval Herishano [Israël] ; Silvia Honigman [Israël] ; Sami Badarny [Israël] ; Eldad Melamed [Israël] | Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease |
| 002672 |
William G. Ondo [États-Unis] ; Joel K. Levy [États-Unis] ; Kevin Dat Vuong [États-Unis] ; Christine Hunter [États-Unis] ; Joseph Jankovic [États-Unis] | Olanzapine treatment for dopaminergic-induced hallucinations |
| 002680 |
Maria C. Obinu [France] ; Michel Reibaud [France] ; Véronique Blanchard [France] ; Saliha Moussaoui [France] ; Assunta Imperato [France] | Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence |
| 002686 |
Craig D. Mccoll [Australie] ; Katrina A. Reardon [Australie] ; Mark Shiff [Australie] ; Peter A. Kempster [Australie] | Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease |
| 002700 |
| MAO-B inhibitors for the treatment of Parkinson's disease |
| 002702 |
G-Y. R. Hsiung [Canada] ; S. K. Das [Canada] ; R. Ranawaya [Canada] ; A.-L. Lafontaine [Canada] ; O. Suchowersky [Canada] | Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period |
| 002704 |
Elena Meseguer [Espagne] ; Rocio Taboada [Espagne] ; Vicenta Sanchez [Espagne] ; Maria Angeles Mena [Espagne] ; Victor Campos [Espagne] ; Justo Garcia De Yebenes [Espagne] | Life-threatening parkinsonism induced by Kava-Kava |
| 002705 |
| Levodopa |
| 002706 |
Miriam Velez [Pérou] ; Carlos Cosentino [Pérou] ; Luis Torres [Pérou] | Levodopa-responsive rubral (Holmes') tremor |
| 002707 |
Gurutz Linazasoro [Espagne] ; Nadege Van Blercom [Espagne] ; Asier Lasa [Espagne] | Levodopa-induced ocular dyskinesias in Parkinson's disease |
| 002708 |
Petr Kanovsky [République tchèque] ; Dagmar Kubova [République tchèque] ; Martin Bares [République tchèque] ; Hana Hortova [République tchèque] ; Hana Streitova [République tchèque] ; Ivan Rektor [République tchèque] ; Vladimir Znojil [République tchèque] | Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up |
| 002709 |
Jong-Min Kim [Corée du Sud] ; KI HYEONG LEE [Corée du Sud] ; Yoon-La Choi [Corée du Sud] ; GI YEONG CHOE [Corée du Sud] ; Beom S. Jeon [Corée du Sud] | Levodopa-induced dyskinesia in an autopsy-proven case of progressive supranuclear palsy |
| 002710 |
Marie-Paule Muriel [France] ; Gaël Orieux [France] ; Etienne C. Hirsch [France] | Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in Parkinsonian rats |
| 002711 |
Anjan Chatterjee [États-Unis] ; Elan D. Louis [États-Unis] ; Steven Frucht [États-Unis] | Levetiracetam in the treatment of paroxysmal kinesiogenic choreoathetosis |
| 002720 |
J. J. Bob Van Hilten [Pays-Bas] ; Willem-Johan T. Van De Beek [Pays-Bas] ; Johan H. C. Voormolen [Pays-Bas] ; Elmer M. Delhaas [Pays-Bas] | Intrathecal baclofen treatment of dystonia in reflex sympathetic dystrophy |
| 002727 |
Valerie E. Kelly [États-Unis] ; Allie S. Hyngstrom [États-Unis] ; Melissa M. Rundle [États-Unis] ; Amy J. Bastian [États-Unis] | Interaction of levodopa and cues on voluntary reaching in Parkinson's disease |
| 002728 |
Luc J. P. Defebvre [France] ; Pierre Krystkowiak [France] ; Jean-Louis Blatt [France] ; Alain Duhamel [France] ; Jean-Louis Bourriez [France] ; Myriame Perina [France] ; Serge Blond [France] ; Jean-Daniel Guieu [France] ; Alain Destée [France] | Influence of pallidal stimulation and levodopa on gait and preparatory postural adjustments in Parkinson's disease |
| 002753 |
Michael R. Pranzatelli [États-Unis] ; Elizabeth D. Tate [États-Unis] ; Marcel Kinshourne [États-Unis] ; Verne S. Jr Caviness [États-Unis] ; Bibhuti Mishra [États-Unis] | Forty-one-year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: Cerebellar atrophy, multiphasic relapses, and response to IVIG |
| 002765 |
J. Carsten Moller [Allemagne] ; Karin Stiasny [Allemagne] ; Volker Hargutt [Allemagne] ; Werner Cassel [Allemagne] ; Heiko Tietze [Allemagne] ; J. Hermann Peter [Allemagne] ; H.-Peter Krüger [Allemagne] ; Wolfgang H. Oertel [Allemagne] | Evaluation of sleep and driving performance in six patients with Parkinson's disease reporting sudden onset of sleep under dopaminergic medication: A pilot study |
| 002771 |
Ashfaq A. Sharif [États-Unis] | Entacapone in restless legs syndrome |
| 002779 |
Willibald Gerschlager [Royaume-Uni] ; Peter Brown [Royaume-Uni] | Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome |
| 002780 |
Julie A. Robichaud [États-Unis] ; Kerstin D. Pfann [États-Unis] ; Cynthia L. Comella [États-Unis] ; Daniel M. Corcos [États-Unis] | Effect of medication on EMG patterns in individuals with Parkinson's disease |
| 002787 |
| Drugs to treat urinary frequency, urgency, and/or urge incontinence |
| 002788 |
| Drugs to treat gastrointestinal motility problems |
| 002789 |
| Drugs to treat dementia and psychosis |
| 002790 |
| Drugs to treat autonomic dysfunction in Parkinson's disease |
| 002792 |
Oleh Hornykiewicz [Autriche] | Dopamine miracle: From brain homogenate to dopamine replacement |
| 002793 |
Monica J. Ling [Australie] ; Arun Aggarwal [Australie] ; John G. L. Morris [Australie] | Dopa-responsive parkinsonism secondary to right temporal lobe haemorrhage |
| 002797 |
J. E. Rice [Australie] ; R. Antic [Australie] ; Philip D. Thompson [Australie] | Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease |
| 002807 |
Diego Garcia-Borreguero [Espagne] ; Ana B. Caminero [Espagne] ; Yolanda De La Llave [Espagne] ; Oscar Larrosa [Espagne] ; Soledad Barrio [Espagne] ; Juan J. Granizo [Espagne] ; Juan A. Pareja [Espagne] | Decreased phasic EMG activity during Rapid eye movement sleep in treatment-naïve Parkinson's disease: Effects of treatment with levodopa and progression of illness |
| 002808 |
| DA agonists: ergot derivatives: Bromocriptine |
| 002809 |
| DA agonists: Non-Ergot derivatives: Ropinirole |
| 002810 |
| DA agonists: Non-Ergot derivatives: Pramipexole |
| 002811 |
| DA agonists: Non-Ergot derivatives: Piribedil |
| 002812 |
| DA agonists: Non-Ergot derivatives: Apomorphine |
| 002813 |
| DA agonists: Ergot derivatives: Pergolide |
| 002814 |
| DA agonists: Ergot derivatives: Lisuride |
| 002815 |
| DA agonists: Ergot derivatives: Dihydroergocryptine (DHEC) |
| 002816 |
| DA agonists: Ergot derivatives: Cabergoline |
| 002826 |
Azi H. Rajput [Canada] ; Mark E. Fenton [Canada] ; Sam Birdi [Canada] ; Rob Macaulay [Canada] ; David George [Canada] ; Bohdar Rozdilsky [Canada] ; Lee C. Ang [Canada] ; Ambikaipakan Senthilselvan [Canada] ; Oleh Hornykiewicz [Autriche] | Clinical-pathological study of levodopa complications |
| 002834 |
Joanne E. Nash [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Characterisation of striatal NMDA receptors involved in the generation of Parkinsonian symptoms: Intrastriatal microinjection studies in the 6-OHDA-lesioned rat |
| 002838 |
Jakob Christensen [Danemark] ; Erik Dupont [Danemark] ; Karen Stergaard [Danemark] | Cabergoline plasma concentration is increased during concomitant treatment with itraconazole |
| 002839 |
| COMT inhibitors |
| 002842 |
Dirk Dressler [Royaume-Uni] ; Hans Bigalke [Allemagne] | Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy |
| 002843 |
C. Detrembleur [Belgique] ; T. M. Lejeune [Belgique] ; A. Renders [Belgique] ; P. Y. K. Van Den Bergh [Belgique] | Botulinum toxin and short-term electrical stimulation in the treatment of equinus in cerebral palsy |
| 002847 |
Francesc Valldeoriola [Espagne] ; Manuela Pilleri [Espagne] ; Eduardo Tolosa [Espagne] ; José L. Molinuevo [Espagne] ; Jordi Rumia [Espagne] ; Enric Ferrer [Espagne] | Bilateral subthalamic stimulation monotherapy in advanced Parkinson's disease: Long-term follow-up of patients |
| 002850 |
David J. Burn [Royaume-Uni] | Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease |
| 002851 |
Mikko Kuoppam Ki [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Michael Jackson [Royaume-Uni] ; Lance Smith [Royaume-Uni] ; Bai-Yun Zeng [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa |
| 002858 |
Alice J. Manson [Royaume-Uni] ; Kirsten Turner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients |
| 002859 |
| Anticholinergic therapies in the treatment of Parkinson's disease |
| 002863 |
| Amantadine and other antiglutamate agents |
| 002867 |
Marcelo Merello [Argentine] ; Maria I. Nouzeilles [Argentine] ; Gabriel Piran Arce [Argentine] ; Ramon Leiguarda [Argentine] | Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis |
| 002879 |
A. Saverino [Italie] ; C. Solaro [Italie] ; E. Capello [Italie] ; C. Trompetto [Italie] ; G. Abbruzzese [Italie] ; A. Schenone [Italie] | Tremor associated with benign IgM paraproteinaemic neuropathy successfully treated with gabapentin |
| 002880 |
Frithjof Tergau [Allemagne] ; Stephan Wischer [Allemagne] ; Christian Wolf [Allemagne] ; Walter Paulus [Allemagne] | Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine |
| 002881 |
Han-Cheng Wang [Taïwan] ; YOLOUNG HSIEH [Taïwan] | Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy |
| 002882 |
Carla Cordivari [Royaume-Uni] ; V. Peter Misra [Royaume-Uni] ; Santiago Catania [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Treatment of dystonic clenched fist with botulinum toxin |
| 002884 |
J. Thomas Hutton [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Jorge L. Juncos [États-Unis] ; William C. Koller [États-Unis] ; Rajesh Pahwa [États-Unis] ; Peter A. Lewitt [États-Unis] ; Ali Samii [Canada] ; Joseph K. C. Tsui [Canada] ; Donald B. Calne [Canada] ; Cheryl H. Waters [États-Unis] ; Vincent P. Calabrese [États-Unis] ; James P. Bennett [États-Unis] ; Richard Barrett [États-Unis] ; Jerry L. Morris [États-Unis] | Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study |
| 002897 |
F. Tracik [Allemagne] ; G. Ebersbach [Allemagne] | Sudden daytime Sleep onset in Parkinson's disease: Polysomnographic recordings |
| 002899 |
Mahmut Edip Gürol [Turquie] ; Mustafa Ertas [Turquie] ; Hasmet Ayhan Hanagasi [Turquie] ; Hüseyin Alparslan Sahin [Turquie] ; Gencay Gürsoy [Turquie] ; Murat Emre [Turquie] | Stiff leg syndrome: Case report |
| 002910 |
Paul J. Reading [Royaume-Uni] ; Anna K. Luce [Royaume-Uni] ; Ian G. Mckeith [Royaume-Uni] | Rivastigmine in the treatment of Parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial |
| 002911 |
Oum-Kaltoum Hassani [France] ; Mireille Mouroux [France] ; Georg Andrees Bohme [France] ; Jean-Marie Stutzmann [France] ; Jean Feger [France] | Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain |
| 002919 |
William Koller [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; Miroslava Doder [Royaume-Uni] ; Mariese Hely [Australie] | Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations |
| 002927 |
Anette Schrag [Royaume-Uni] ; Michael Trimble [Royaume-Uni] | Poetic talent unmasked by treatment of Parkinson's disease |
| 002930 |
Virgilio Gerald H. Evidente [Philippines] | Piribedil for restless legs syndrome: A pilot study |
| 002931 |
Jon H. Falkenberg [États-Unis] ; Paul A. Laizzo [États-Unis] ; Linda K. Mcloon [États-Unis] | Physiological assessment of muscle strength in vitro after direct injection of Doxorubicin into rabbit sternocleidomastoid muscle |
| 002946 |
J. Hoenicka [Espagne] ; L. Vidal [Espagne] ; M. Godoy [Espagne] ; J. J. Ochoa [Espagne] ; J. Garcia De Yebenes [Espagne] | New nonsense mutation in the GTP-cyclohydrolase I gene in L-DOPA responsive dystonia-parkinsonism |
| 002949 |
P. H. Gordon [États-Unis] ; S. J. Frucht [États-Unis] | Neuroleptic malignant syndrome in advanced Parkinson's disease |
| 002955 |
R. Richard Sloop [États-Unis] ; Dorothee Cole [États-Unis] ; Milan C. Patel [États-Unis] | Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals |
| 002961 |
Tobias E. Eichhorn [Allemagne] ; Wolfgang H. Oertel [Allemagne] | Macrogol 3350/Electrolyte improves constipation in Parkinson's disease and multiple system atrophy |
| 002964 |
Jean-Louis Montastruc [France] ; Karine Desboeuf [France] ; Maryse Lapeyre-Mestre [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Christine Brefel-Courbon [France] | Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease |
| 002965 |
Arthur S. Walters [États-Unis] ; Juliane Winkelmann [Allemagne] ; Claudia Trenkwalder [Allemagne] ; June M. Fry [États-Unis] ; Vandana Kataria [États-Unis] ; Mary Wagner [États-Unis] ; Rakesh Sharma [États-Unis] ; Wayne Hening [États-Unis] ; LIREN LI [États-Unis] | Long-term follow-up on restless legs syndrome patients treated with opioids |
| 002966 |
Fabrizio Stocchi [Italie] ; Laura Vacca [Italie] ; Alfredo Berardelli [Italie] ; Francesca De Pandis [Italie] ; Stefano Ruggieri [Italie] | Long-duration effect and the postsynaptic compartment : Study using a dopamine agonist with a short half-life |
| 002971 |
Birgit Högl [Autriche] ; Md. Klaus Seppi [Autriche] ; Elisabeth Brandauer [Autriche] ; Gregor Wenning [Autriche] ; Werner Poewe [Autriche] | Irresistible onset of sleep during acute levodopa challenge in a patient with multiple system atrophy: Placebo-controlled, polysomnographic case report |
| 002973 |
Paolo Del Dotto [Italie] ; Nicola Pavese [Italie] ; Gianna Gambaccini [Italie] ; Silvia Bernardini [Italie] ; Leonard Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Ubaldo Bonuccelli [Italie] | Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study |
| 002980 |
Olivier Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France] | Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease |
| 002981 |
Maria D. Benedetti [États-Unis] ; Demetrius M. Maraganore [États-Unis] ; James H. Bower [États-Unis] ; Shannon K. Mcdonnell [États-Unis] ; Brett J. Peterson [États-Unis] ; J. Eric Ahlskog [États-Unis] ; Daniel J. Schaid [États-Unis] ; Walter A. Rocca [États-Unis] | Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study |
| 002A15 |
Jorg Müller [Autriche] ; Georg Ebersbach [Autriche] ; Jorg Wissel [Autriche] ; Werner Poewe [Autriche] | Dynamic balance function in phasic cervical dystonia following Botulinum toxin therapy |
| 002A28 |
Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie] | Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease |
| 002A33 |
Stewart A. Factor [États-Unis] ; Joseph H. Friedman [États-Unis] ; Margaret C. Lannon [États-Unis] ; David Oakes [États-Unis] ; Keith Bourgeois [États-Unis] | Clozapine for the treatment of drug-induced psychosis in Parkinson's disease : Results of the 12 week open label extension in the PSYCLOPS trial |
| 002A36 |
Krishna P. Datla [Royaume-Uni] ; Stavia B. Blunt [Royaume-Uni] ; David T. Dexter [Royaume-Uni] | Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl3 nigrostriatal lesions |
| 002A44 |
JINWHAN CHO [Corée du Sud] ; KON CHU [Corée du Sud] ; Beom S. Jeon [Corée du Sud] | Case of essential palatal tremor: Atypical features and remarkable benefit from botulinum toxin injection |
| 002A76 |
| Abstracts from International Conference 1999: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Orlando, FL, USA, November 16-18, 1999 |
| 002A78 |
C. W. Olanow [États-Unis] ; A. H. V. Schapira [Royaume-Uni] ; T. Roth [États-Unis] | Waking up to sleep episodes in Parkinson's disease |
| 002A88 |
D. Dressler [Allemagne] ; M. Wittstock [Allemagne] ; R. Benecke [Allemagne] | Treatment of persistent hemiballism with botulinum toxin type A |
| 002A91 |
Silvana Tesei [Italie] ; Angelo Antonini [Italie] ; Margherita Canesi [Italie] ; Anna Zecchinelli [Italie] ; Claudio B. Mariani [Italie] ; Gianni Pezzoli [Italie] | Tolerability of paroxetine in Parkinson's disease : A prospective study |
| 002A92 |
R. A. Hauser [États-Unis] ; W. C. Koller [États-Unis] ; J. P. Hubble [États-Unis] ; T. Malapira [États-Unis] ; K. Busenbark [États-Unis] ; C. W. Olanow [États-Unis] | Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease |
| 002A95 |
L. M. Shulman [États-Unis] ; A. Minagar [États-Unis] ; A. Rabinstein [États-Unis] ; W. J. Weiner [États-Unis] | The use of dopamine agonists in very elderly patients with Parkinson's disease |
| 002A96 |
Hasmet A. Hanagasi [Turquie] ; Gülüstü Kaptanoglu [Turquie] ; Hüseyin A. Sahin [Turquie] ; Murat Emre [Turquie] | The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa |
| 002B03 |
C. Ramaker [Pays-Bas] ; W. J. T. Van De Beek [Pays-Bas] ; M. J. J. Finken [Pays-Bas] ; B. J. J. Van Hilten [Pays-Bas] | The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications : A systematic review |
| 002B05 |
I. Reuter [Royaume-Uni] ; S. Harder [Allemagne] ; M. Engelhardt [Allemagne] ; H. Baas [Allemagne] | The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa |
| 002B17 |
T. A. Zesiewicz [États-Unis] ; M. Helal [États-Unis] ; R. A. Hauser [États-Unis] | Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's Disease |
| 002B21 |
Alessandro Di Rocco [États-Unis] ; John D. Rogers [États-Unis] ; Richard Brown [États-Unis] ; Peter Werner [États-Unis] ; Teodoro Bottiglieri [États-Unis] | S-Adenosyl-methionine improves depression in patients with Parkinson's disease in an open-label clinical trial |
| 002B22 |
N. A. Leopold [États-Unis] | Risperidone treatment of drug-related psychosis in patients with Parkinsonism |
| 002B23 |
Erich Mohr [Canada] ; Tilak Mendis [Canada] ; Kathleen Hildebrand [Canada] ; Peter Paul De Deyn [Belgique] | Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial |
| 002B25 |
Kevin J. Black [États-Unis] ; Jonathan W. Mink [États-Unis] | Response to levodopa challenge in Tourette syndrome |
| 002B35 |
K. F. Bhattacharya [Royaume-Uni] ; I. Giannakikou [Royaume-Uni] ; N. Munroe [Royaume-Uni] ; K. Ray Chaudhuri [Royaume-Uni] | Primary anticholinergic-responsive pisa syndrome |
| 002B40 |
C. G. Goetz [États-Unis] ; T. Q. Vu ; P. M. Carvey ; S. Leurgans | Posthypoxic myoclonus in the rat : Natural history, stability, and serotonergic influences |
| 002B46 |
Pieter Joost Van Wattum [États-Unis] ; Phillip B. Chappell [États-Unis] ; Daniel Zelterman [États-Unis] ; Lawrence D. Scahill [États-Unis] ; James F. Leckman [États-Unis] | Patterns of response to acute naloxone infusion in Tourette's syndrome |
| 002B47 |
A. Brashear [États-Unis] ; K. Bergan [États-Unis] ; J. Wojcieszek [États-Unis] ; E. R. Siemers [États-Unis] ; W. Ambrosius [États-Unis] | Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A |
| 002B48 |
José Antonio Molina [Espagne] ; Maria José Sainz-Artiga [Espagne] ; Talicia Fraile [Espagne] ; Félix Javier Jimenez-Jimenez [Espagne] ; Clara Villanueva [Espagne] ; Miguel Orti-Pareja [Espagne] ; Félix Bermeio-P [Espagne] | Pathologic gambling in Parkinson's disease : A behavioral manifestation of pharmacologic treatment? |
| 002B69 |
Robert A. Hauser [États-Unis] ; Mervat N. Wahba [États-Unis] ; Theresa A. Zesiewicz [États-Unis] ; W. Mcdowell Anderson [États-Unis] | Modafinil treatment of pramipexole-associated somnolence |
| 002B76 |
S. Frucht [États-Unis] ; S. Fahn [États-Unis] ; S. Chin [États-Unis] ; V. Dhawan [États-Unis] ; D. Eidelberg [États-Unis] | Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration |
| 002B83 |
Doron Merims [Israël] ; Ronit Galili-Mosberg [Israël] ; Eldad Melamed [Israël] | Is there addiction to levodopa in patients with Parkinson's disease? |
| 002B87 |
Ruth H. Walker [États-Unis] ; Fabio O. Danisi [États-Unis] ; David M. Swope [États-Unis] ; Robert R. Goodman [États-Unis] ; Isabelle M. Germano [États-Unis] ; Mitchell F. Brin [États-Unis] | Intrathecal baclofen for dystonia: Benefits and complications during six years of experience |
| 002B91 |
T. E. Kimber [Australie] ; P. D. Thompson [Australie] | Increased blink rate in advanced Parkinson's disease : A form of 'off'-period dystonia? |
| 002B93 |
M. D. Welsh [États-Unis] ; T. Dorflinger [États-Unis] ; D. Chernik [États-Unis] ; C. Waters [États-Unis] | Illness Impact and Adjustment to Parkinson's disease : Before and after treatment with tolcapone |
| 002B94 |
A. J. Manson [Royaume-Uni] ; E. Iakovidou [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease |
| 002C00 |
W. Ondo [États-Unis] ; C. Hunter [États-Unis] ; K. Dat Vuong [États-Unis] ; K. Schwartz [États-Unis] ; Joseph Jankovic [États-Unis] | Gabapentin for Essential tremor : A multiple-dose, double-blind, placebo-controlled trial |
| 002C04 |
Francisco Cardoso [Brésil] ; José Teotonio De Oliveira [Brésil] ; Marzia Puccioni-Sohler [Brésil] ; Alexandre R. Fernandes [Brésil] ; James Pitagoras De Mattos [Brésil] ; Iscia Lopes-Cendes [Brésil] | Eyelid dystonia in Machado-Joseph disease |
| 002C17 |
H. H. Fernandez [États-Unis] ; J. H. Friedman ; J. Grace [États-Unis] ; S. Beason-Hazen [États-Unis] | Donepezil for Huntington's disease |
| 002C23 |
N. L. W. Keijsers [Pays-Bas] ; M. W. I. M. Horstink [Pays-Bas] ; J. J. Van Hilten [Pays-Bas] ; J. I. Hoff [Pays-Bas] ; C. C. A. M. Gielen [Pays-Bas] | Detection and assessment of the severity of levodopa-induced dyskinesia in patients with Parkinson's disease by neural networks |
| 002C32 |
H. H. Fernandez [États-Unis] ; M. C. Lannon [États-Unis] ; J. H. Friedman [États-Unis] ; B. P. Abbott [États-Unis] | Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease |
| 002C37 |
J. Kulisevsky [Espagne] ; C. Garcia-Sanchez [Espagne] ; M. L. Berthier [Espagne] ; M. Barbanoj [Espagne] ; B. Pascual-Sedano [Espagne] ; A. Gironell [Espagne] ; A. Estevez-Gonzalez [Espagne] | Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease : A two-year follow-up study of previously untreated patients |
| 002C38 |
David Devos [France] ; Luc Defebvre [France] ; Alain Destée [France] ; Jacques Caron [France] | Choreic movements induced by cibenzoline : An Ic class antiarrhythmic effect? |
| 002C42 |
Dirk Dressler [Allemagne] ; Uwe Zettl [Allemagne] ; Reiner Benecke [Allemagne] ; Hans Bigalke [Allemagne] | Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure? |
| 002C45 |
H. Apaydin [Turquie] ; S. Ertan [Turquie] ; S. Özekmekci [Turquie] | Broad bean (Vicia faba) : A natural source of L-dopa : Prolongs "on" periods in patients with Parkinson's disease who have "on-off" fluctuations |
| 002C46 |
A. Rapaport [Israël] ; M. Sadeh [Israël] ; D. Stein [Israël] ; J. Levine [Israël] ; P. Sirota [Israël] ; T. Mosheva [Israël] ; S. Stir [Israël] ; A. Elitzur [Israël] ; I. Reznik [Israël] ; D. Geva [Israël] ; J. M. Rabev [Israël] | Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia |
| 002C52 |
E. Luginger [Autriche] ; G. K. Wenning [Autriche] ; S. Bosch [Autriche] ; Werner Poewe [Autriche] | Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's Disease |
| 002C53 |
K. Ray Chaudhuri [Royaume-Uni] ; M. T. M. Hu [Royaume-Uni] ; D. J. Brooks [Royaume-Uni] | Atypical parkinsonism in Afro-Caribbean and Indian origin immigrants to the UK |
| 002C54 |
J. H. Friedman [États-Unis] ; S. A. Factor | Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease |
| 002C57 |
Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] | Apomorphine : An underutilized therapy for Parkinson's disease |
| 002C67 |
V. G. H. Evidente [États-Unis, Philippines] ; C. H. Adler [États-Unis] ; J. N. Caviness [États-Unis] ; J. G. Hentz [États-Unis] ; K. Gwinn-Hardy [États-Unis] | Amantadine is beneficial in restless legs syndrome |
| 002C87 |
E. S. Molho [États-Unis] ; S. A. Factor [États-Unis] | Worsening of motor features of Parkinsonism with olanzapine |
| 002C96 |
P. Kanovsky [République tchèque] ; H. Streitova [République tchèque] ; M. Bares [République tchèque] ; H. Hortova [République tchèque] | Treatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A : Evidence of a long-lasting effect |
| 002C97 |
J. L. Montastruc [France] ; Olivier Rascol [France] ; J.-M. Senard [France] | Treatment of Parkinson's disease should begin with a dopamine agonist |
| 002C98 |
S. A. Factor [États-Unis] ; E. S. Molho [États-Unis] | Transient benefit of amantadine in Parkinson's disease : The facts about the myth |
| 002D01 |
B. Henry [Royaume-Uni] ; S. H. Fox [Royaume-Uni] ; D. Peggs [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Royaume-Uni] | The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-Parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease |
| 002D04 |
W. J. Weiner [États-Unis] | The initial treatment of Parkinson's disease should begin with levodopa |
| 002D07 |
J. E. Ahlskog [États-Unis] ; R. J. Uitti [États-Unis] ; M. K. O'Connor [États-Unis] ; D. M. Maraganore [États-Unis] ; J. Y. Matsumoto [États-Unis] ; K. F. Stark [États-Unis] ; M. F. Turk [États-Unis] ; O. L. Burnett [États-Unis] | The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease |
| 002D09 |
S. Spieker [Allemagne] ; P.-A. Löschmann [Allemagne] ; T. Klockgether [Allemagne] | The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations |
| 002D11 |
B. Safirstein [États-Unis] ; L. M. Shulman [États-Unis] ; W. J. Weiner [États-Unis] | Successful treatment of hemichorea with olanzapine |
| 002D14 |
A. Lagueny [France] ; F. Tison [France] ; P. Burbaud [France] ; G. Le Masson [France] ; P. Kien [France] | Stimulus-sensitive spinal segmental myoclonus improved with injections of botulinum toxin type A |
| 002D16 |
M. S. Moreau [France] ; A. Severac Cauquil [France] ; M. C. Costes Salon [France] | Static and dynamic balance function in spasmodic torticollis |
| 002D22 |
A. Churchyard [Royaume-Uni] ; C. J. Mathias [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Selegiline-induced postural hypotension in Parkinson's disease : A longitudinal study on the effects of drug withdrawal |
| 002D27 |
W. Ondo [États-Unis] ; MD [États-Unis] | Ropinirole for restless legs syndrome |
| 002D28 |
V. G. H. Evidente [États-Unis, Philippines] ; K. Gwinn-Hardy [États-Unis] ; J. N. Caviness [États-Unis] ; C. H. Adler [États-Unis] | Risperidone is effective in severe hemichorea/hemiballismus |
| 002D29 |
H. D. Rosas [États-Unis] ; W. J. Koroshetz [États-Unis] ; B. G. Jenkins [États-Unis] ; Y. I. Chen [États-Unis] ; D. L. Hayden [États-Unis] ; M. F. Beal [États-Unis] ; M. E. Cudkowicz [États-Unis] | Riluzole therapy in Huntington's Disease (HD) |
| 002D32 |
A. Schrag [Royaume-Uni] ; L. Schelosky [Allemagne] ; U. Scholz [Allemagne] ; Werner Poewe [Autriche] | Reduction of parkinsonian signs in patients with parkinson's disease by dopaminergic versus anticholinergic single-dose challenges |
| 002D34 |
H. H. Fernandez [États-Unis] ; J. H. Friedman [États-Unis] ; C. Jacques [États-Unis] ; M. Rosenfeld [États-Unis] | Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease |
| 002D48 |
G. Lera [Argentine] ; J. Zirulnik [Argentine] | Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced Parkinsonism |
| 002D51 |
G. J. Brewer [États-Unis] | Penicillamine should not be used as initial therapy in Wilson's disease |
| 002D52 |
J. M. Walshe [Royaume-Uni] | Penicillamine : The treatment of first choice for patients with Wilson's disease |
| 002D60 |
L. E. Davis [États-Unis] ; J. C. Adair [États-Unis] | Parkinsonism from methanol poisoning : Benefit from treatment with anti-Parkinson drugs |
| 002D67 |
D. Tarsy [États-Unis] ; E. R. First [États-Unis] | Painful cervical dystonia : Clinical features and response to treatment with botulinum toxin |
| 002D74 |
J. Kimber [Royaume-Uni] ; L. Watson ; C. J. Mathias | Neuroendocrine responses to levodopa in multiple system atrophy (MSA) |
| 002D76 |
K. R. Müller-Vahl [Allemagne] ; U. Schneider [Allemagne] ; H. M. Emrich [Allemagne] | Nabilone increases choreatic movements in Huntington's disease |
| 002D85 |
S. Ohara [Japon] ; J. Tsuyuzaki [Japon] ; R. Hayashi [Japon] | Mexiletine in the treatment of blepharospasm : Experience with the first three patients |
| 002D86 |
N. Giladi [Israël] ; H. Shabtai [Israël] | Melatonin-induced withdrawal emergent dyskinesia and akathisia |
| 002D87 |
D. Kunz [Allemagne] ; F. Bes [Allemagne] | Melatonin as a therapy in REM sleep behavior disorder patients : An open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation |
| 002D88 |
F. Le Doze [France] ; M. Moulin [France] ; G.-L. Defer [France] | Meige's syndrome in a patient treated with ranitidine |
| 002D93 |
N. Giladi [Israël] ; E. Melamed [Israël] | Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism |
| 002E02 |
F. Stocchi [Italie] ; C. Farina [Italie] ; G. Nordera [Italie] ; S. Ruggieri [Italie] | Implantable venous access system for apomorphine infusion in complicated Parkinson's disease |
| 002E21 |
A. S.-I. Pakiam [Canada] ; A. E. Lang [Canada] | Essential palatal tremor : Evidence of heterogeneity based on clinical features and response to sumatriptan |
| 002E24 |
| Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients |
| 002E25 |
R. B. Innis [États-Unis] ; K. L. Marek [États-Unis] ; K. Sheff [États-Unis] ; S. Zoghbi [États-Unis] ; J. Castronuovo [États-Unis] ; A. Feigin [États-Unis] ; J. P. Seibyl [États-Unis] | Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]β-CIT |
| 002E26 |
R. Chen [États-Unis, Canada] ; B. I. Karp [États-Unis] ; S. R. Goldstein [États-Unis] ; W. Bara-Jimenez [États-Unis] ; Z. Yaseen [États-Unis] ; M. Hallett [États-Unis] | Effect of muscle activity immediately after botulinum toxin injection for writer's cramp |
| 002E46 |
T. Mezaki [Japon] ; R. Kaji [Japon] ; M. F. Brin [États-Unis] ; M. Hirota-Katayama [Japon] ; T. Kubori [Japon] ; T. Shimizu [Japon] ; J. Kimura [Japon] | Combined use of type A and F botulinum toxins for blepharospasm : A double-blind controlled trial |
| 002E54 |
M. J. Rosenfeld [États-Unis] ; J. H. Friedman [États-Unis] | Catatonia responsive to lorazepam : A case report |
| 002E55 |
G. Northoff [Allemagne] ; A. Koch [Allemagne] ; J. Wenke [Allemagne] ; J. Eckert [Allemagne] ; H. Böker [Allemagne] ; B. Pflug [Allemagne] ; B. Bogerts [Allemagne] | Catatonia as a psychomotor syndrome : A rating scale and extrapyramidal motor symptoms |
| 002E65 |
E. Grünblatt [Israël] ; S. Mandel [Israël] ; T. Berkuzki [Israël] ; M. B. H. Youdim [Israël] | Apomorphine protects against MPTP-induced neurotoxicity in mice |
| 002E66 |
M. Merello [Argentine] ; J. Balej [Argentine] ; M. Delfino [Argentine] ; A. Cammarota [Argentine] ; O. Betti [Argentine] ; R. Leiguarda [Argentine] | Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease |
| 002E67 |
E. Moro [Italie] ; A. Albanese [Italie, Suisse] | Apomorphine and levodopa challenge in patients with a focal midbrain lesion |
| 002E71 |
B. I. Karp [États-Unis, Canada] ; S. R. Goldstein [États-Unis, Canada] ; R. Chen [États-Unis, Canada] ; A. Samii [États-Unis] ; W. Bara-Jimenez [États-Unis, Canada] ; M. Hallett [États-Unis, Canada] | An open trial of clozapine for dystonia |
| 002E73 |
R. Ceravolo [Italie] ; S. Salvetti [Italie] ; P. Piccini [Royaume-Uni] ; C. Lucetti [Italie] ; G. Gambaccini [Italie] ; U. Bonuccelli [Italie] | Acute and chronic effects of clozapine in essential tremor |
| 002E74 |
M. Onofrj [Italie] ; A. Thomas [Italie] | Acetazolamide-responsive periodic ataxia induced by amiodarone |
| 002E78 |
J.-L. Montastruc [France] ; M. Ziegler [France] ; Olivier Rascol [France] ; M. Malbezin [France] | A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease |
| 002E80 |
W. Ondo [États-Unis] ; C. Hunter [États-Unis] ; M. Almaguer [États-Unis] ; Joseph Jankovic [États-Unis] | A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease |
| 002E93 |
I. Shoulson [États-Unis] | Where do we stand on neuroprotection? Where do we go from here? |
| 002E95 |
M. R. Trimble [Royaume-Uni] ; R. Whurr [Royaume-Uni] ; G. Brookes [Royaume-Uni] ; M. M. Robertson [Royaume-Uni] | Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections |
| 002E96 |
F. Ovsiew [États-Unis] ; K. J. Meador [États-Unis] ; K. Sethi [États-Unis] | Verapamil for severe hyperkinetic movement disorders |
| 002E97 |
C. Sankhla [États-Unis] ; Joseph Jankovic [États-Unis] ; D. Duane [États-Unis] | Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections |
| 002F03 |
J. Winkelmann [Allemagne] ; T. C. Wetter [Allemagne] ; K. Stiasny [Allemagne] ; W. H. Oertel [Allemagne] ; C. Trenkwalder [Allemagne] | Treatment of restless leg syndrome with pergolide : An open clinical trial |
| 002F04 |
M. Bakar [Turquie] ; M. Zarifoglu [Turquie] ; I. Bora [Turquie] ; F. Turan [Turquie] ; C. Sen [Turquie] ; E. Ogul [Turquie] | Treatment of hereditary trembling chin with botulinum toxin |
| 002F07 |
J.-M. Gerard [Belgique] ; F. Delecluse [Belgique] ; Y. Robience [Belgique] | Theophylline-induced stuttering |
| 002F10 |
T. Van Laar [Pays-Bas] ; B. Van Hilten [Pays-Bas] ; C. Neef [Pays-Bas] ; A. W. F. Rutgers [Pays-Bas] ; S. Pavel [Pays-Bas] ; J. A. Bruijn [Pays-Bas] | The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease : A histologic study |
| 002F15 |
N. Syed [États-Unis] ; J. Murphy [États-Unis] ; T. Jr Zimmerman [États-Unis] ; M. H. Mark [États-Unis] ; J. I. Sage [États-Unis] | Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease |
| 002F16 |
D. J. Burn [Royaume-Uni] ; A. Coulthard [Royaume-Uni] ; S. Connolly [Royaume-Uni] ; N. E. F. Cartlidge [Royaume-Uni] | Tardive diaphragmatic flutter |
| 002F17 |
P. Sachdev [Australie] | Tardive blepharospasm |
| 002F21 |
P. Van Den Munckhof [États-Unis] ; F. A. Lenz [États-Unis] ; T. N. Chase [États-Unis] ; L. V. Metman [États-Unis] | Square-wave action dystonia in Parkinson's disease |
| 002F24 |
A. Kupsch [Allemagne] ; W. H. Oertel [Allemagne] | Selegiline, pregnancy, and Parkinson's disease |
| 002F25 |
A. D. Korczyn [Israël] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; F. Stocchi [Italie] | Ropinirole versus bromocriptine in the treatment of early Parkinson's disease : A 6-month interim report of a 3-year study |
| 002F26 |
Olivier Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; A. D. Korczyn [Israël] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] | Ropinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study |
| 002F41 |
P. Hagell [Suède] ; P. Odin [Allemagne] ; E. Vinge [Suède] | Pregnancy in Parkinson's disease : A review of the literature and a case report |
| 002F43 |
P. C. Jacob [Oman] ; R. Pratap Chand [Oman] | Posttraumatic rubral tremor responsive to clonazepam |
| 002F51 |
P. G. Wasielewski [États-Unis] ; J. M. Burns [États-Unis] ; W. C. Koller [États-Unis] | Pharmacologic treatment of tremor |
| 002F54 |
S. M. Mirsattari [Canada] ; C. Power [Canada] ; A. Nath [Canada, États-Unis] | Parkinsonism with HIV infection |
| 002F68 |
D. Dressler [Royaume-Uni] ; T. Scaravilli [Royaume-Uni] ; K. P. Bhatia [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] | Nicotine nasal spray is not reliable treatment for blepharospasm : Results of a pilot study |
| 002F74 |
V. P. Calabrese [Canada] ; K. A. Lloyd [Canada] ; P. Brancazio [Canada] ; E. Cefali [États-Unis] ; P. Martin [États-Unis] ; J. Jr Wall [États-Unis] ; D. Sica [États-Unis] | N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism |
| 002F77 |
M. R. Pranzatelli [États-Unis] ; Y.-Y. Huang [États-Unis] ; E. Tate [États-Unis] ; D. S. Goldstein [États-Unis] ; C. S. Holmes [États-Unis] ; E. M. Goldstein [États-Unis] ; K. Ketner [États-Unis] ; M. Kinast ; B. M. Lange [États-Unis] ; A. Sanz [États-Unis] ; M. I. Shevell [Canada] ; R. E. Stanford ; I. P. Taff [États-Unis] | Monoaminergic effects of high-dose corticotropin in corticotropin-responsive pediatric opsoclonus-myoclonus |
| 002F78 |
S. Ohara [Japon] ; R. Hayashi [Japon] ; H. Momoi [Japon] ; J. Miki [Japon] ; N. Yanagisawa [Japon] | Mexiletine in the treatment of spasmodic torticollis |
| 002F86 |
N. R. Hughes [Royaume-Uni] ; A. T. Mcknight [Royaume-Uni] ; G. N. Woodruff [Royaume-Uni] ; M. P. Hill [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Royaume-Uni] | Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism |
| 002F88 |
A. Dalvi [États-Unis] ; S. Fahn [États-Unis] ; B. Ford [États-Unis] | Intrathecal baclofen in the treatment of dystonic storm |
| 002F89 |
P. Krack [France] ; Pierre Pollak [France] ; P. Limousin [France] ; D. Hoffmann [France] ; A. Benazzouz [France] ; Alim-Louis Benabid [France] | Inhibition of levodopa effects by internal pallidal stimulation |
| 003011 |
J. D. O'Sullivan [Australie] ; C. M. Said [Australie] ; L. C. Dillon [Australie] ; M. Hoffman [Australie] ; A. J. Hughes [Australie] | Gait analysis in patients with Parkinson's disease and motor fluctuations : Influence of levodopa and comparison with other measures of motor function |
| 003013 |
J. A. Loeb [États-Unis] | Functional improvement in a patient with cerebral calcinosis using a bisphosphonate |
| 003021 |
C. L. Comella [États-Unis] ; K. M. Shannon [États-Unis] ; J. Jaglin [États-Unis] | Extensor truncal dystonia : Successful treatment with botulinum toxin injections |
| 003027 |
J. S. Schneider [États-Unis] ; A. Pope-Coleman [États-Unis] ; M. Van Velson [États-Unis] ; F. Menzaghi [États-Unis] ; G. K. Lloyd [États-Unis] | Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys |
| 003028 |
V. G. H. Evidente [États-Unis] ; C. H. Adler [États-Unis] ; J. N. Caviness [États-Unis] ; K. A. Gwinn [États-Unis] | Effective treatment of orthostatic tremor with gabapentin |
| 003029 |
C. M. Gudex [Danemark] ; M. R. Hawthorne [Royaume-Uni] ; A. G. Butler [Royaume-Uni] ; P. Duffey [Royaume-Uni] | Effect of dystonia and botulinum toxin treatment on health-related quality of life |
| 003030 |
Olivier Rascol [France] ; K. Sieradzan [Royaume-Uni] ; H. Peyro-Saint-Paul [France] ; C. Thalamas [France] ; C. Brefel-Courbon [France] ; J. M. Senard [France] ; P. Ladure [France] ; J. L. Montastruc [France] ; A. Lees [Royaume-Uni] | Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy |
| 003034 |
J. Warren [Australie] ; P. Thompson [Australie] | Drug-induced supraglottic dystonia and spasmodic dysphonia |
| 003035 |
R. Pahwa [États-Unis] ; K. Lyons [États-Unis] ; J. P. Hubble [États-Unis] ; K. Busenbark [États-Unis] ; J. D. Rienerth [États-Unis] ; A. Pahwa [États-Unis] ; W. C. Koller [États-Unis] | Double-blind controlled trial of gabapentin in essential tremor |
| 003038 |
A. P. Payne [Royaume-Uni] ; R. G. Sutcliffe [Royaume-Uni] ; J. M. Campbell [Royaume-Uni] ; G. Favor [Royaume-Uni] ; D. Russell [Royaume-Uni] ; N. K. Bennett [Royaume-Uni] ; D. J. Clarke [Royaume-Uni] ; R. Branton [Royaume-Uni] ; R. W. Davies [Royaume-Uni] ; E. Simpson [Royaume-Uni] ; C. Tsang [Royaume-Uni] ; R. H. Baxendale [Royaume-Uni] | Disordered locomotion in the AS/AGU mutant rat and the effects of L-dopa or fetal midbrain grafts |
| 003044 |
R. K. B. Pearce [Royaume-Uni] ; T. Banerji ; P. Jenner ; C. D. Marsden | De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset |
| 003046 |
C. W. Olanow [États-Unis] ; C. Mytilineou [États-Unis] ; W. Tatton [États-Unis] | Current status of selegiline as a neuroprotective agent in Parkinson's disease |
| 003047 |
R. C. Dodel [Allemagne] ; K. M. Eggert [Allemagne] ; M. S. Singer [Allemagne] ; T. E. Eichhorn [Allemagne] ; O. Pogarell [Allemagne] ; W. H. Oertel [Allemagne] | Costs of drug treatment in Parkinson's disease |
| 003052 |
P. A. Lewitt [États-Unis] | Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease |
| 003053 |
M. Merello [Argentine] ; A. Cammarota [Argentine] ; M. I. Nouzeilles [Argentine] ; O. Betti [Argentine] ; R. Leiguarda [Argentine] | Confirmation of the antidyskinetic effect of posteroventral pallidotomy by means of an intraoperative apomorphine test |
| 003054 |
I. M. Bronner [Pays-Bas] ; J. A. L. Vanneste [Pays-Bas] | Complex movement disorder associated with fluvoxamine |
| 003055 |
A. Brashear [États-Unis] ; W. T. Ambrosius [États-Unis] ; G. J. Eckert [États-Unis] ; E. R. Siemers [États-Unis] | Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A |
| 003057 |
R. M. Trosch [États-Unis] ; J. H. Friedman [États-Unis] ; M. C. Lannon [États-Unis] ; R. Pahwa [États-Unis] ; D. Smith [États-Unis] ; L. C. Seeberger [États-Unis] ; C. F. O'Brien [États-Unis] ; P. A. Lewitt [États-Unis] ; W. C. Koller [États-Unis] | Clozapine use in Parkinson's disease : A retrospective analysis of a large multicentered clinical experience |
| 003058 |
I. Maurer [Allemagne] ; T. Grunwald [Allemagne] ; C. E. Elger [Allemagne] | Clozapine treatment of delayed-onset paroxysmal hemidystonia |
| 003059 |
H. H. Fernandez [États-Unis] ; R. Durso [États-Unis] | Clozapine for dopaminergic-induced paraphilias in Parkinson's disease |
| 003065 |
J. F. Marti-Masso [Espagne] ; J. J. Poza [Espagne] | Cinnarizine-induced Parkinsonism : Ten years later |
| 003067 |
P. Katlovsky [République tchèque] ; H. Streitova [République tchèque] ; J. Dufek [République tchèque] ; V. Znojil [République tchèque] ; P. Daniel [République tchèque] ; I. Rektor [République tchèque] | Change in lateralization of the P22/N30 cortical component of median nerve somatosensory evoked potentials in patients with cervical dystonia after successful treatment with botulinum toxin A |
| 003075 |
S. Dethy [Belgique] ; N. Van Blercom [Belgique] ; P. Damhaut [Belgique] ; D. Wikler [Belgique] ; J. Hildebrand [Belgique] ; S. Goldman [Belgique] | Asymmetry of basal ganglia glucose metabolism and dopa responsiveness in parkinsonism |
| 003079 |
J. D. O'Sullivan [Australie] ; A. J. Hughes [Australie] | Apomorphine-induced penile erections in Parkinson's disease |
| 003081 |
M. Gassen [Israël] ; A. Gross [Israël] ; M. B. H. Youdim [Israël] | Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine |
| 003082 |
T. Van Laar [Pays-Bas] ; G.-J. Lammers [Pays-Bas] ; R. A. C. Roos [Pays-Bas] ; J. J. Gerritsen [Pays-Bas] ; A. E. Meinders [Pays-Bas] | Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion |
| 003085 |
P. J. Blanchet [États-Unis] ; S. Konitsiotis [États-Unis] ; T. N. Chase [États-Unis] | Amantadine reduces levodopa-induced dyskinesias in Parkinsonian monkeys |
| 003087 |
M. F. Mendez [États-Unis] ; A. Mirea | Adult head-banging and stereotypic movement disorders |
| 003088 |
J. M. Brotchie [Royaume-Uni] | Adjuncts to dopamine replacement : A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease |
| 003094 |
L. V. Metman [États-Unis] ; P. J. Blanchet [États-Unis] ; P. Van Den Munckhof [États-Unis] ; P. Del Dotto [États-Unis] ; R. Natte [États-Unis] ; T. N. Chase [États-Unis] | A trial of dextromethorphan in Parkinsonian patients with motor response complications |
| 003095 |
P. A. Lapchak [États-Unis] | A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease |
| 003096 |
R. A. Hauser [États-Unis] ; E. Molho [États-Unis] ; H. Shale [États-Unis] ; S. Pedder [États-Unis] ; E. E. Dorflinger [États-Unis] | A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients |
| 003097 |
R. B. Jr Dewey [États-Unis] ; D. M. Maraganore [États-Unis] ; J. E. Ahlskog [États-Unis] ; J. Y. Matsumoto [États-Unis] | A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease |
| 003099 |
F. Delecluse [Belgique] ; J. A. Elosegi [Belgique] ; J.-M. Gerard [Belgique] | A case of tardive tremor successfully treated with clozapine |
| 003102 |
J. Schwarz [Allemagne] ; K. Tatsch [Allemagne] ; T. Gasser [Allemagne] ; G. Arnold [Allemagne] ; O. Pogarell [Allemagne] ; G. Künig [Allemagne] ; W. H. Oertel [Allemagne] | 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism |
| 003106 |
J. Schwarz [Allemagne] ; K. Tatsch [Allemagne] ; T. Gasser ; G. Arnold ; W. H. Oertel | [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy |
| 003116 |
S. Ohara [Japon] ; J. Miki [Japon] ; H. Momoi [Japon] ; H. Unno [Japon] ; M. Shindo [Japon] ; N. Yanagisawa [Japon] | Treatment of spasmodic torticollis with mexiletine : A case report |
| 003118 |
E. Dupont [Danemark] ; J.-M. Burgunder [Suisse] ; L. J. Findley [Royaume-Uni] ; J.-E. Olsson [Suède] ; E. Dorflinger [États-Unis] | Tolcapone added to levodopa in stable parkinsonian patients : A double-blind placebo-controlled study |
| 003121 |
E. J. Pappert [États-Unis] ; J. W. Lipton [États-Unis] ; C. G. Goetz [États-Unis] ; Z. D. Ling [États-Unis] ; G. T. Stebbins [États-Unis] ; P. M. Carvey [États-Unis] | The stability of carbidopa in solution |
| 003125 |
P. Lewitt [États-Unis] ; D. Oakes [États-Unis] ; L. Cui [États-Unis] | The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α-tocopherol |
| 003126 |
S. A. Factor [États-Unis] ; J. H. Friedman [États-Unis] | The emerging role of clozapine in the treatment of movement disorders |
| 003127 |
J. P. Larsen [Norvège] ; J. Boas [Danemark] | The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability : An interim analysis of a Norwegian-Danish 5-year study |
| 003129 |
F. Lobbezoo [Canada] ; G. J. Lavigne [Canada] ; R. Tanguay [Canada] ; J. Y. Montplaisir [Canada] | The effect of the catecholamine precursor L-dopa on sleep bruxism : A controlled clinical trial |
| 003134 |
K. R. Kessler [Allemagne] ; R. Benecke [Allemagne] | The EDB test : A clinical test for the detection of antibodies to botulinum toxin type A |
| 003140 |
A. Meyer-Lindenberg [Allemagne] ; B. Krausnick [Allemagne] | Tardive dyskinesia in a neuroleptic-naive patient with bipolar-I disorder : Persistent exacerbation after lithium intoxication |
| 003143 |
N. J. Diederich [Luxembourg (pays), États-Unis] ; C. L. Comella [États-Unis] ; G. Matge [Luxembourg (pays)] ; G. Becker [Luxembourg (pays)] ; F. Schiltz [Luxembourg (pays)] ; H. Metz [Luxembourg (pays)] | Sustained effect of high-dose intrathecal baclofen in primary generalized dystonia : A 2-year follow-up study |
| 003144 |
M. Poyurovsky [Israël] ; M. Schneidman [Israël] ; A. Weizman [Israël] | Successful treatment of fluoxetine-induced dystonia with low-dose mianserin |
| 003146 |
A. Burleigh-Jacobs [États-Unis] ; F. B. Horak [États-Unis] ; J. G. Nutt [États-Unis] ; J. A. Obeso [Espagne] | Step initiation in Parkinson's disease : Influence of levodopa and external sensory triggers |
| 003148 |
B. Ford [États-Unis] ; S. L. Pullman [États-Unis] ; A. Khandji [États-Unis] ; R. Goodman [États-Unis] | Spinal myoclonus induced by an intrathecal catheter |
| 003151 |
J. Lyytinen [Finlande] ; S. Kaakkola [Finlande] ; S. Ahtila [Finlande] ; P. Tuomainen [Finlande] ; H. Ter V Inen [Finlande] | Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with Parkinson's disease |
| 003152 |
M. Zappia [Italie] ; R. Montesanti [Italie] ; R. Colao [Italie] ; D. Branca [Italie] ; G. Nicoletti [Italie] ; U. Aguglia [Italie] ; A. Quattrone [Italie] | Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease |
| 003155 |
D. Dressler [Allemagne] ; R.-O. Oeljesch Ger [Allemagne] ; E. Rüther [Allemagne] | Severe tardive dystonia: Treatment with continuous intrathecal baclofen administration |
| 003156 |
A. Albanese ; G. Maria [Italie] ; A. Bentivoglio ; T. Brisinda [Italie] ; E. Cassetta [Italie] ; P. Tonali | Severe constipation in Parkinson's disease relieved by botulinum toxin |
| 003157 |
R. A. Hauser [États-Unis] ; T. A. Zesiewicz [États-Unis] | Sertraline for the treatment of depression in Parkinson's disease |
| 003161 |
G. Meco [Italie] ; A. Alessandri [Italie] ; P. Giustini [Italie] ; V. Bonifati [Italie] | Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study |
| 003166 |
J. Wissel [Allemagne, Autriche] ; F. Masuhr [Allemagne] ; L. Schelosky [Allemagne] ; G. Ebersbach [Allemagne, Autriche] ; Werner Poewe [Autriche] | Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor |
| 003177 |
MYUNG SIK LEE [Corée du Sud] ; CHUL HYOUNG LYOO [Corée du Sud] ; WON CHAN KIM [Corée du Sud] ; HO JEONG KANG [Corée du Sud] | Periodic bursts of rhythmic dyskinesia associated with spinal anesthesia |
| 003198 |
G. Dziewczapolski [Argentine] ; L. B. Menalled [Argentine] ; M. T. Savino [Argentine] ; M. Mora [Argentine] ; F. J. E. Stefano [Argentine] ; O. Gershanik [Argentine] | Mechanism of action of clozapine-induced modification of motor behavior in an animal model of the "super-off" phenomenon |
| 003201 |
J. H. Friedman [États-Unis] | Machado-Joseph disease/spinocerebellar ataxia 3 responsive to buspirone |
| 003202 |
W. H. Jost [Allemagne] ; K. Schimrigk [Allemagne] | Long-term results with cisapride in Parkinson's disease |
| 003209 |
A. H. Rajput [Canada] ; M. E. Fenton [Canada] ; S. Birdi [Canada] ; R. Macaulay [Canada] | Is levodopa toxic to human substantia nigra? |
| 003217 |
P. A. Lewitt [États-Unis] ; R. M. Trosch [États-Unis] | Idiosyncratic adverse reactions to intramuscular botulinum toxin type a injection |
| 003218 |
K. Ikeda [Japon] ; M. Kinoshita [Japon] ; K. Aoki [Japon] ; A. Tomatsuri [Japon] | Hydrocephalic parkinsonism due to Paget's disease of bone : Dramatic improvement following ventriculoperitoneal shunt and temporary levodopa/carbidopa therapy |
| 003223 |
P. Chana [Chili] ; A. De Marinis [Chili] ; N. Barrientos [Chili] | Gabapentin and motor fluctuations in Parkinson's disease |
| 003232 |
L. A. Smith [Royaume-Uni] ; A. Gordin [Finlande] ; P. Jenner [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] | Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets |
| 003236 |
I. Soykan [États-Unis] ; I. Sarosiek [États-Unis] ; J. Shifflett [États-Unis] ; G. F. Wooten [États-Unis] ; R. W. Mccallum [États-Unis] | Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease |
| 003237 |
J. F. Lipinski [États-Unis] ; F. R. Sallee [États-Unis] ; C. Jackson [États-Unis] ; G. Sethuraman [États-Unis] | Dopamine agonist treatment of Tourette disorder in children : Results of an open-label trial of pergolide |
| 003246 |
C. Sampaio [Portugal] ; J. J. Ferreira [Portugal] ; F. Simoes [Portugal] ; M. J. Rosas [Portugal] ; M. Magalhaes [Portugal] ; A. P. Correia [Portugal] ; A. Bastos-Lima [Portugal] ; R. Martins [Portugal] ; A. Castro-Caldas [Portugal] | DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-dysport and botox-assuming a ratio of 4:1 |
| 003250 |
W. Ashraf [États-Unis] ; R. F. Pfeiffer [États-Unis] ; F. Park [États-Unis] ; J. Lof [États-Unis] ; E. M. M. Quigley [États-Unis] | Constipation in Parkinson's disease : Objective assessment and response to psyllium |
| 003254 |
R. Pahwa [États-Unis] ; K. Lyons [États-Unis] ; D. Mcguire [États-Unis] ; P. Silverstein [États-Unis] ; F. Zwiebel [États-Unis] ; M. Robischon [États-Unis] ; W. C. Koller [États-Unis] | Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease : Pharmacokinetic and quality-of-life measures |
| 003255 |
D. Tarsy [États-Unis] | Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin |
| 003259 |
S. B. Blunt [Royaume-Uni] ; R. J. M. Lane [Royaume-Uni] ; N. Turjanski [Royaume-Uni] ; G. D. Perkin [Royaume-Uni] | Clinical features and management of two cases of Encephalitis lethargica |
| 003271 |
N. Giladi [Israël] ; S. Honigman [Israël] | Botulinum toxin injections to one leg alleviate freezing of gait in a patient with Parkinson's disease |
| 003272 |
R. Liguori [Italie] ; C. Cordivari [Italie] ; E. Lugaresi [Italie] ; P. Montagna [Italie] | Botulinum toxin a improves muscle spasms and rigidity in Stiff-Person syndrome |
| 003273 |
D. D. Truong [États-Unis] ; P. A. Cullis [États-Unis] ; C. F. O'Brien [États-Unis] ; M. Koller [États-Unis] ; T. P. Villegas [États-Unis] ; J. D. Wallace [États-Unis] | BotB (botulinum toxin type B): Evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study) |
| 003295 |
P. G. Como [États-Unis] ; A. J. Rubin [États-Unis] ; C. F. O'Brien [États-Unis] ; K. Lawler [États-Unis] ; C. Hickey [États-Unis] ; A. E. Rubin [États-Unis] ; R. Henderson [États-Unis] ; M. P. Mcdermott [États-Unis] ; T. Mcdermott [États-Unis] ; K. Steinberg [États-Unis] ; I. Shoulson [États-Unis] | A controlled trial of fluoxetine in nondepressed patients with Huntington's disease |
| 003304 |
P. Girlanda [Italie] ; A. Quartarone ; S. Sinicropi ; C. Nicolosi ; C. Massina | Unilateral injection of botulinum toxin in blepharospasm : single fiber electromyography and blink reflex study |
| 003309 |
B. L. Scott [États-Unis] ; R. W. Evans [États-Unis] ; Joseph Jankovic [États-Unis] | Treatment of palatal myoclonus with sumatriptan |
| 003311 |
F. Stocchi [Italie] ; M. F. De Pandis [Italie] ; F. A. Delfino [Italie] ; T. Anselmo [Italie] ; D. Frongillo [Italie] | Transient atrial fibrillation after subcutaneous apomorphine bolus |
| 003312 |
M. Y. Neufeld [Israël] ; P. Nisipeanu [Israël] ; V. Chistik [Israël] ; A. D. Korczyn [Israël] | The electroencephalogram in acetazolamide-responsive periodic ataxia |
| 003314 |
M. Raja [Italie] ; G. Maisto [Italie] ; M. C. Altavista [Italie] ; A. Albanese [Italie] | Tardive lingual dystonia treated with clozapine |
| 003319 |
C. Raftopoulos [Belgique] ; S. Dethy ; M. A. Laute ; S. Goldman ; A. B. Naini ; S. Przedborski ; J. Hildebrand | Slow increase of homovanillic acid in cerebrospinal fluid after levodopa administration |
| 003325 |
P. E. Greene [États-Unis] ; S. Fahn [États-Unis] | Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients |
| 003328 |
A. Tan [États-Unis] ; M. Salgado [États-Unis] ; S. Fahn [États-Unis] | Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa |
| 003335 |
F. Picard [France] ; A. De Saint-Martin [France] ; E. Salmon [Belgique] ; E. Hirsch [France] ; C. Marescaux [France] | Postencephalitic stereotyped involuntary movements responsive to L-Dopa |
| 003336 |
R. Pahwa [États-Unis] ; J. Marjama [États-Unis] ; D. Mcguire [États-Unis] ; K. Lyons [États-Unis] ; F. Zwiebel ; P. Silverstein ; R. Ward ; W. C. Koller [États-Unis] | Pharmacokinetic comparison of Sinemet and atamet (generic carbidopa/levodopa) : A single-dose study |
| 003338 |
C. H. Adler [États-Unis] ; R. S. Zimmerman ; M. K. Lyons ; F. Simeone ; M. F. Brin | Perioperative use of botulinum toxin for movement disorder-induced cervical spine disease |
| 003352 |
E. J. Pappert [États-Unis] ; C. Buhrfiend ; J. W. Lipton ; P. M. Carvey ; G. T. Stebbins ; C. G. Goetz | Levedopa stability in solution : time course, environmental effects, and practical recommendations for clinical use |
| 003357 |
B. R. Bloem [Pays-Bas] ; D. J. Beckley [États-Unis] ; J. G. Van Dijk [Pays-Bas] ; A. H. Zwinderman [Pays-Bas] ; M. P. Remler [États-Unis] ; R. A. C. Roos [Pays-Bas] | Influence of dopaminergic medication on automatic postural responses and balance impairment in Parkinson's disease |
| 003376 |
F. Tison [France] ; L. Wiart [France] ; M. Guatterie [France] ; N. Fouillet [France] ; V. Lozano [France] ; P. Henry [France] ; M. Barat [France] | Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease |
| 003377 |
L. V. Metman [États-Unis] ; P. J. Blanchet [États-Unis] ; D. De Jong [États-Unis] ; M. M. Mouradian [États-Unis] ; T. N. Chase [États-Unis] | Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease |
| 003379 |
P. J. Blanchet [Canada] ; R. Grondin ; P. J. Bedard | Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates |
| 003387 |
K. J. Bharucha [États-Unis] ; K. D. Sethi [États-Unis] | Complex movement disorders induced by fluoxetine |
| 003388 |
A. Ikeda [Japon] ; .. Shibasaki [Japon] ; K. Tashiro [Japon] ; Y. Mizuno [Japon] ; J. Kimura [Japon] | Clinical trial of piracetam in patients with myoclonus : nationwide multiinstitution study in Japan |
| 003397 |
G. Geminiani [Italie] ; V. Fetoni [Italie] ; S. Genitrini [Italie] ; P. Giovannini [Italie] ; F. Tamma [Italie] ; T. Caraceni [Italie] | Cabergoline in Parkinson's disease complicated by motor fluctuations |
| 003401 |
G. W. Paulson [États-Unis] ; W. Gill [États-Unis] | Botulinum toxin is unsatisfactory therapy for fibromyalgia |
| 003402 |
B. L. Scott [États-Unis] ; Joseph Jankovic [États-Unis] ; D. T. Donovan | Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome |
| 003403 |
S. Salloway [États-Unis] ; C. F. Stewart [États-Unis] ; L. Israeli ; X. Morales ; S. Resmussen [États-Unis] ; A. Blitzer [États-Unis] ; M. F. Brin [États-Unis] | Botulinum toxin for refractory vocal tics |
| 003407 |
D.-E. Shan [Taïwan] ; S.-Y. Kwan [Taïwan] ; H.-H. Ho [Taïwan] ; M.-S. Su [Taïwan] | Belly dystonia induced by levodopa and biperiden in a case of suspected multiple-system atrophy |
| 003411 |
A. Feigin [États-Unis] ; K. Kieburtz [États-Unis] ; P. Como [États-Unis] ; C. Hickey [États-Unis] ; K. Claude [États-Unis] ; D. Abwender [États-Unis] ; C. Zimmerman [États-Unis] ; K. Steinberg [États-Unis] ; I. Shoulson [États-Unis] | Assessment of coenzyme Q10 tolerability in Huntington's disease |
| 003412 |
A. P. Sempere [Espagne] ; J. Duarte [Espagne] ; F. Garcia [Espagne] ; C. Cabezas [Espagne] ; F. Coria [Espagne] ; L. E. Claveria [Espagne] | An estimate of the risk of movement disorders associated with the chronic use of clebopride |
| 003413 |
L. Smith [Royaume-Uni] ; M. De Salvia [Royaume-Uni] ; P. Jenner [Royaume-Uni] ; C. D. Marsden | An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets |
| 003416 |
P. J. Blanchet [États-Unis] ; L. V. Metman [États-Unis] ; M. M. Mouradian [États-Unis] ; T. N. Chase [États-Unis] | Acute pharmacologic blockade of dyskinesias in Parkinson's disease |
| 003420 |
Joseph Jankovic [États-Unis] ; K. Schwartz [États-Unis] ; W. Clemence [États-Unis] ; A. Aswad ; J. Mordaunt | A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor |
| 003421 |
T. Van Laar [Pays-Bas] ; C. Neef [Pays-Bas] ; M. Danhof [Pays-Bas] ; K. I. Roon [Pays-Bas] ; R. A. C. Roos [Pays-Bas] | A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease |
| 003423 |
K. Kieburtz [États-Unis] ; A. Feigin ; M. Mcdermott ; P. Como ; D. Abwender ; C. Zimmerman ; C. Hickey ; C. Orme ; K. Claude ; J. Sotack ; J. T. Greenamyre ; C. Dunn ; I. Shoulson | A controlled trial of remacemide hydrochloride in Huntington's disease |
| 003424 |
N. G. Ranen [États-Unis] ; C. E. Peyser [États-Unis] ; J. T. Coyle [États-Unis] ; F. W. Bylsma [États-Unis] ; M. Sherr [États-Unis] ; L. Day [États-Unis] ; M. F. Folstein [États-Unis] ; J. Brandt [États-Unis] ; C. A. Ross [États-Unis] ; S. E. Folstein [États-Unis] | A controlled trial of idebenone in Huntington's disease |
| 003436 |
R. Lindeboom [Pays-Bas] ; R. De Haan ; M. Aramideh ; J. D. Speelman | The blepharospasm disability scale : an instrument for the assessment of functional health in blepharospasm |
| 003462 |
T. Van Laar [Pays-Bas] ; E. N. H. Jansen ; C. Neef ; M. Danhof ; R. A. C. Roos | Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease : a study of five different suppositories |
| 003492 |
G. Ebersbach [Allemagne] ; C. Kabus ; L. Schelosky [Allemagne] ; L. Terstegge ; Werner Poewe [Allemagne] | Hemimasticatory spasm in hemifacial atrophy : diagnostic and therapeutic aspects in two patients |
| 003505 |
R. Cole [États-Unis] ; M. Hallett ; L. G. Cohen | Double-blind trial of botulinum toxin for treatment of focal hand dystonia |
| 003519 |
M. H. Mark [États-Unis] ; J. I. Sage ; A. S. Walters ; R. C. Duvoisin ; D. C. Miller | Binswanger's disease presenting as levodopa-responsive parkinsonism : clinicopathologic study of three cases |
| 003524 |
N. J. Scolding [Royaume-Uni] ; S. M. Smith [Royaume-Uni] ; S. Sturman ; G. B. Brookes [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Auctioneer's jaw : a case of occupational oromandibular hemidystonia |
| 003567 |
C. G. Goetz [États-Unis] ; G. T. Stebbins ; J. A. Thelen | Talipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo-controlled clinical trial |
| 003568 |
T. Mendis [Canada] ; E. Mohr [Canada] ; A. George ; I. N. Rusk [Canada] ; P. Gray ; J. D. Grimes | Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride |
| 003595 |
J. D. Belluzzi [États-Unis] ; E. F. Domino ; J. M. May ; K. S. Bankiewicz ; D. A. Mcafee | N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease |
| 003600 |
M. Merello [Argentine] ; H. Garcia ; M. Nogues ; R. Leiguarda | Masticatory muscle spasms in a non-japanese patient with satoyoshi syndrome successfully treated with botulinum toxin |
| 003603 |
S. S. Rich [États-Unis] ; F. Ovsiew | Leuprolide acetate for exhibitionism in Huntington's disease |
| 003610 |
G. E. Borodic [États-Unis] ; R. Ferrante ; L. Bruce Pearce ; K. Smith [États-Unis] | Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections |
| 003623 |
K. B. Polo [États-Unis] ; BAHMAN JABBARI | Effectiveness of botulinum toxin type A against painful limb myoclonus of spinal cord origin |
| 003628 |
P. Greene [États-Unis] ; S. Fahn [États-Unis] ; B. Diamond | Development of resistance to botulinum toxin type A in patients with torticollis |
| 003631 |
J. H. Friedman [États-Unis] | Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases |
| 003633 |
S. Rose [Royaume-Uni] ; P. Jenner ; C. D. Marsden | Chronic administration does not alter the accumulation of L-dopa into muscle |
| 003637 |
Joseph Jankovic [États-Unis] | Botulinum toxin in the treatment of dystonic tics |
| 003642 |
R. Pratap Chand [Royaume-Uni] ; D. M. Park | Atypical blepharospasm responsive to sodium valproate |
| 003658 |
P. E. Greene [États-Unis] ; S. Fahn | Use of botulinum toxin Type F injections to treat torticollis in patients with immunity to Botulinum toxin Type A |
| 003662 |
D. Bravi [États-Unis] ; T. L. Davis ; M. M. Mouradian ; T. N. Chase | Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980 |
| 003664 |
M. F. Gordon [États-Unis] ; R. Diaz-Olivo ; A. L. Hunt ; S. Fahn | Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders |
| 003672 |
C. Pacchetti [Italie] ; E. Martignoni [Italie] ; P. Bruggi [Italie] ; L. Godi [Italie] ; B. Aufdembrinke ; C. Miltenburger ; B. Voet ; G. Nappi [Italie] | Terguride in fluctuating Parkinsonian patients: a double-blind study versus placebo |
| 003674 |
H. Allain [France] ; Pierre Pollak [France] ; H. C. Neukirch [France] | Symptomatic effect of selegiline in De Novo Parkinsonian patients |
| 003677 |
A. J. Hughes [Royaume-Uni] ; S. Bishop ; B. Kleedorfer ; N. Turjanski ; W. Fernandez ; Andrew Lees (neurologue) [Royaume-Uni] ; G. M. Stern | Subcateneous apomorphine in Parkinson's disease: response to chronic administration for up to five years |
| 003680 |
B. Johnels [Suède] ; P. E. Ingvarsson [Suède] ; B. Holmberg ; M. Matousek [Suède] ; G. Steg [Suède] | Single-dose L-dopa response in early parkinson's disease : measurements with optoelectronic recording technique |
| 003681 |
D. Davis [États-Unis] ; B. Jabbari | Significant improvement of stiff-person syndrome after paraspinal injection of botulinum toxin A |
| 003682 |
V. V. Myllyl [Finlande] ; K. A. Sotaniemi ; J. A. Vuorinen ; E. H. Heinonen | Selegiline in De Novo Parkinsonian patients: the finnish study |
| 003683 |
W. G. Tatton [Canada] | Selegiline can mediate neuronal rescue rather than neuronal protection |
| 003685 |
C. A. Hubbard [États-Unis] ; J. M. Trugman | Reversal of reserpine-induced catalepsy by selective D1 and D2 dopamine agonists |
| 003691 |
D. Dykstra [États-Unis] ; C. Ellingham ; A. Belfie ; T. Baxter ; M. Lee ; A. Voelker | Quantitative measurement of cervical range of motion in patients with torticollis treated with botulinum A toxin |
| 003696 |
A. Feve [France] ; B. Angelard [France] ; G. Fenelon [France] ; M. Logak [France] ; A. Guillard [France] ; J. Lacau Saint-Guily | Postneuroleptic laryngeal dyskinesias: a cause of upper airway obstructive syndrome improved by local injections of botulinum toxin |
| 003706 |
G. Linazasoro [Espagne] ; J. F. Marti Masso ; J. A. Suarez | Nocturnal akathisia in Parkinson's disease: treatment with clozapine |
| 003711 |
A. Ferbert [Allemagne] ; R. Biniek [Allemagne] ; J. Kindler ; N. Maurin | Myoclonus and tremor induced acutely by administration of tumor necrosis factor in a patient with Ehlers-Danlos syndrome |
| 003713 |
G. J. Gomez Arevalo [Argentine] ; O. S. Gershanik | Modulator effect of clozapine on levodopa response in Parkinson's disease: a preliminary study |
| 003714 |
M. E. Giuffra [États-Unis] ; V. H. Sethy ; T. L. Davis ; M. M. Mouradian ; T. N. Chase | Milacemide therapy for Parkinson's disease |
| 003718 |
J. Vaamonde [Suède] ; I. Legarda [Suède] ; J. Jimenez-Jimenez ; J. L. Zubieta [Suède] ; J. A. Obeso [Suède] | Levodopa-responsive parkinsonism associated with basal ganglia calcification and primary hypoparathyroidism |
| 003723 |
W. S. Metzer [États-Unis] ; S. R. Paige ; J. E. O. Newton | Inefficacy of propranolol in attenuation of drug-induced parkinsonian tremor |
| 003732 |
P. Brown [Royaume-Uni] ; M. J. Steiger [Royaume-Uni] ; P. D. Thompson [Royaume-Uni] ; J. C. Rothwell [Royaume-Uni] ; B. L. Day [Royaume-Uni] ; M. Salama ; T. Waegemans ; C. D. Marsden [Royaume-Uni] | Effectiveness of piracetam in cortical myoclonus |
| 003733 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. Bedard | Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors |
| 003734 |
P. Lamberti [Italie] ; M. De Mari ; G. Iliceto ; M. Caldarola ; L. Serlenga | Effect of L-dopa on oculogyric crises in a case of dopa-responsive dystonia |
| 003735 |
S. A. Factor [États-Unis] ; W. J. Weiner | Early combination therapy with bromocriptine and levodopa in Parkinson's disease |
| 003737 |
J. G. Nutt [États-Unis] ; J. H. Carter ; W. Woodward ; J. P. Hammerstad ; S. T. Gancher | Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions |
| 003742 |
W. H. Jost [Allemagne] ; K. Schimrigk | Cisapride treatment of constipation in Parkinson's disease |
| 003754 |
U. Bonuccelli [Italie] ; P. Piccini [Italie] ; P. Del Dotto [Italie] ; G. Rossi ; G. U. Corsini ; A. Muratorio [Italie] | Apomorphine test for dopaminergic responsiveness: a dose assessment study |
| 003759 |
M. Guttman [Canada] ; G. Leger ; A. Reches ; A. Evans ; H. Kuwabara ; J. M. Cedarbaum ; A. Gjedde | Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa |
| 003761 |
M. Vidailhet [France] ; C. Bouchard [France] ; P. J. Jedynak [France] ; M. Serdaru [France] | Acute and long-term response to apomorphine in cranial dystonia |
| 003762 |
S. A. Factor [États-Unis] | Acetazolamide therapy of menstrual-related fluctuations in Parkinson's disease |
| 003763 |
C. W. Olanow [États-Unis] | A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease |
| 003786 |
B. Jabbari [États-Unis] ; J. Paul ; B. Scherokman ; B. Van Dam | Posttraumatic segmental axial dystonia |
| 003800 |
J.-F. De Saint Victor [France] ; C.-L. Gervason | Levopoda-induced diphasic dyskinesias improved by subcutaneous apomorphine |
| 003801 |
M Contin [Italie] ; R. Riva ; P. Martinelli ; A. Baruzzi | Kinetic-dynamic relationship of oral levopoda : possible biphasic response after sequential doses in Parkinson's disease |
| 003804 |
F. Stocchi [Italie] ; S. Ruggieri ; A. Carta ; J. Ryatt ; N. Quinn ; P. Jenner ; C. D. Marsden ; A. Agnoli | Intravenous boluses and continuous infusions of L-DOPA methyl ester in fluctuating patients with Parkinson's disease |
| 003806 |
I. Rektor [République tchèque] ; M. Svejdova ; C. Silva-Barrat ; C. Menini | Influence of cholinergic systems on myoclonus in myoclonic epilepsies |
| 003818 |
M. Emre [Suisse] ; U. K. Rinne ; A. Rascol ; A. Lees ; Yves Agid [France] ; X. Lataste | Effects of a selective partial D1 agonist, CY 208-243, in De Novo patients with Parkinson disease |
| 003820 |
D. Bravi [États-Unis] ; J. J. Anderson ; F. Dagani ; T. L. Davis ; R. Feerari ; M. Gillespie ; T. N. Chase | Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease |
| 003821 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of Parkinsonism |
| 003823 |
C. E. Clarke [Royaume-Uni] ; J. M. Bamford ; A. House | Dyskinesia in Creutzfeldt-Jakob disease precipitated by antidepressant therapy |
| 003835 |
P. E. Greene [États-Unis] ; S. Fahn | Baclofen in the treatment of idiopathic dystonia in children |
| 003840 |
J. Rivest ; Andrew Lees (neurologue) [Royaume-Uni] ; C. D. Marsden | Writer's cramp : treatment with botulinum toxin injections |
| 003849 |
S. Rittig ; J. Arentsen ; K. Soêrensen ; T. Matthiesen ; E. Dupont | The hemodynamic effects of triglycyl-lysine-vasopressin (glypressin) in patients with parkinsonism and orthostatic hypotension |
| 003850 |
P. Blum ; Joseph Jankovic [États-Unis] | Stiff-Person syndrome : an autoimmune disease |
| 003851 |
S. V. Pavlakis [États-Unis] ; S. Schneider ; K. Black ; R. J. Gould | Steroid-responsive chorea in Moyamoya disease |
| 003852 |
M. J. Steiger ; N. P. Quinn ; C. D. Marsden | Sickness due to levodopa-induced neck dyskinesias in Parkinson's disease |
| 003854 |
A. S. Walters ; W. A. Hening ; SUDHANSU CHOKROVERTY | Review and videotape recognition of idiopathic restless legs syndrome |
| 003855 |
E. Sasso ; E. Perucca ; R. Fava ; S. Calzetti | Quantitative comparison of barbiturates in essential hand and head tremor |
| 003860 |
A. J. Hughes ; Andrew Lees (neurologue) [Royaume-Uni] ; C. D. Marsden | Paroxysmal dystonic head tremor |
| 003863 |
P. M. Fitzgerald ; Joseph Jankovic [États-Unis] | Orthostatic tremor : an association with essential tremor |
| 003865 |
M. J. Steiger ; N. P. Quinn ; B. Toone ; C. D. Marsden | Off-period screaming accompanying motor fluctuations in Parkinson's disease |
| 003871 |
F. Dagani [Italie] ; R. Ferrari ; J. I. Anderson ; T. N. Chase | L-Dopa does not affect electron transfer chain enzymes and respiration of rat muscle mitochondria |
| 003891 |
P. Giovannini ; I. Piccolo ; S. Genitrini ; P. Soliveri ; F. Girotti ; G. Geminiani ; G. Scigliano ; T. Caraceni | Early-onset Parkinson's disease |
| 003904 |
S. T. Gancher ; J. G. Nutt ; W. R. Woodward | Absorption of apomorphine by various routes in parkinsonism |
| 003906 |
P. Brown ; P. D. Thompson ; J. C. Rothwell ; B. L. Day ; C. D. Marsden | A therapeutic trial of milacemide in myoclonus and the Stiff-Person syndrome |
| 003907 |
M. Hallett ; J. Ravits ; R. M. Dubinsky ; M. M. Gillespie ; AMIR MOINFAR | A double-blind trial of isoniazid for essential tremor and other action tremors |
| 003920 |
J. M. Cedarbaum ; M. Clark ; L. H. Toy ; A. Green-Parsons | Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease : evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation |
| 003922 |
N. M. J. Rupniak ; S. J. Tye ; M. J. Steventon ; S. Boyce ; S. D. Iversen | Spontaneous orofacial dyskinesias in a captive cynomolgus monkey : implications for tardive dyskinesia |
| 003936 |
M. E. Rodriguez ; M. R. Luquin ; G. Lera ; G. Delgado ; J. M. Salazar ; J. A. Obeso | Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion |
| 003954 |
U. J. Povlsen ; H. Pakkenberg | Effect of intravenous injection of biperiden and clonazepam in dystonia |
| 003961 |
J. H. Friedman ; M. C. Lannon | Clozapine-responsive tremor in Parkinson's disease |
| 003962 |
R. F. Pfeiffer ; J. Kang ; B. Graber ; R. Hofman ; J. Wilson | Clozapine for psychosis in Parkinson's disease |
| 003966 |
Werner Poewe [Autriche] ; G. Luef ; B. Kleedorfer ; M. Emre | Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease |
| 003973 |
M. Sano ; Y. Stern ; K. Marder ; R. Mayeux | A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease |
| 003981 |
B. Jabbari ; B. Scherokman ; C. H. Gunderson ; M. L. Rosenberg ; J. Miller | Treatment of movement disorders with trihexylphenidyl |
| 003983 |
Fh. Mcdowell | The use of glutethimide for treatment of essential tremor |
| 003986 |
R. J. Coleman ; K. W. Lange ; N. P. Quinn ; A. E. Loper ; J. V. Bondi ; M. Hitchens ; S. M. Stahl ; C. D. Marsden | The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+ PHNO): preliminary results |
| 003987 |
R. E. Burke ; UN JUNG KANG ; Joseph Jankovic [États-Unis] ; L. C. Miller ; S. Fahn | Tardive akathisia: an analysis of clinical features and response to open therapeutic trials |
| 003994 |
C. H. Adler ; M. B. Stern ; M. L. Brooks | Parkinsonism secondary to bilateral striatal fungal abscesses |
| 003997 |
P. A. Kempster ; Andrew Lees (neurologue) [Royaume-Uni] ; P. Crichton ; J. P. Fkankel ; P. Shorvon | Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine |
| 003998 |
F. E. Micheli ; M. M. Fernandez Pardal ; R. Giannaula ; M. Gatto ; I. Casas Parera ; G. Paradiso ; M. Torres ; R. Pikielny ; J. Fernandez Pardal | Movement disorders and depression due to flunarizine and cinnarizine |
| 003A07 |
E. Pourcher ; A.-M. Bonnet ; J. Kefalos ; B. Dubois ; Yves Agid [France] | Effects of etybenzatropine and diazepam on Levodopa-induced diphasic dyskinesias in Parkinson's disease |
| 003A08 |
E. Mohr ; G. Fabbrini ; J. Williams ; J. Schlegel ; C. Cox ; P. Fedio ; T. N. Chase | Dopamine and memory function in Parkinson's disease |
| 003A09 |
Joseph Jankovic [États-Unis] ; K. Schwartz ; C. Vander Linden | Comparison of Sinemet CR4 and standars Sinemet: double blind and long-term open trial in Parkinsonian patients with fluctuations |
| 003A14 |
R. F. Pfeiffer ; L. H. Herrera ; C. S. Glaeske ; R. E. Hofman | CQP A01-403 in Parkinson's disease: an open-label pilot study |
| 003A18 |
J. A. Temlett ; N. P. Quinn ; P. G. Jenner ; C. D. Marsden ; E. Pourcher ; A.-M. Bonnet ; Y. Acid ; R. Markstein ; X. Lataste | Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease |
| 003A19 |
M. F. Brin ; A. Blitzer ; S. Fahn ; W. Gould ; R. E. Lovelace | Adductor laryngeal dystonia (Spastic dysphonia): treatment with local injections of botulinum toxoin (Botox) |
| 003A27 |
D. Dung Truong ; S. Fahn | Therapeutic trial with glycine in myoclonus |
| 003A34 |
R. L. Albin ; A. B. Young | Somatosensory phenomena in Huntington's disease |
| 003A43 |
G. Pezzoli ; S. Tesei ; C. Ferrante ; E. Cossutta ; A. Zecchinelli ; G. Scarlato | Madopar HBS in fluctuating Parkinsonian patients: two-year treatment |
| 003A45 |
O. S. Gershanik ; M. R. Luquin ; O. Scipioni ; J. A. Obeso | Isoniazid therapy in Parkinson's disease |
| 003A47 |
D. Dung Truong ; J. Garcia De Yebenes ; G. Pezzoli ; V. Jackson-Lewis ; S. Fahn | Glycine involvement in DDT-induced myoclonus |
| 003A50 |
M. Hietanen ; H. Teravainen | Dementia and treatment with L-dopa in Parkinson's disease |
| 003A57 |
E. Lehkuniec ; F. Micheli ; R. De Arbelaiz ; M. Torres ; G. Paradiso | Concurrent hypnogenic and reflex paroxysmal dystonia |
| 003A58 |
S. Ruggieri ; F. Stocchi ; A. Carta ; D. Bravi ; M. Bragoni ; L. Giorgi ; A. Agnoli | Comparison between L-dopa and lisuride intravenous infusions: a clinical study |
| 003A62 |
P. Greene ; H. Shale ; S. Fahn | Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs |
| 003A69 |
C. G. Goetz ; K. M. Shannon ; V. S. Carroll ; C. M. Tanner ; R. Weingarten | The autonomic nervous system in Gilles de la Tourette's syndrome |
| 003A76 |
M. F. Brin ; S. Fahn ; C. Moskowitz ; A. Friedman ; H. M. Shale ; P. E. Greene ; A. Blitzer ; T. List ; D. Lange ; R. E. Lovelace ; D. Mcmahon | Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm |
| 003A77 |
M. R. Samie ; M. A. Dannenhoffer ; S. Rozek | Life-threatening tardive dyskinesia caused by metoclopramide |
| 003A78 |
J. L. Montastruc ; P. Celsis ; A. Agniel ; J. F. Demonet ; B. Doyon ; M. Puel ; J. P. Marc-Vergnes ; A. Rascol | Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease: lack of correlation with clinical or neuropsychological improvements |
| 003A87 |
B. Jabbari ; M. Rosenberg ; B. Scherokman ; C. H. Gunderson ; J. W. Mcburney ; W. Mcclintock | Effectiveness of trihexyphenidyl against pendular nystagmus and palatal myoclonus: evidence of cholinergic dysfunction |
| 003A96 |
F. Grandas ; N. Quinn ; P. Critchley ; A. Rohan ; C. D. Marsden ; S. M. Stahl | Antiparkinsonian activity of a single oral dose of PHNO |
| 003A97 |
N. Nomoto ; S. Stahl ; P. Jenner ; C. D. Marsden | Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset |
| 003A98 |
M. Nomoto ; P. D. Thompson ; M. P. Sheehy ; N. P. Quinn ; C. D. Marsden | Anticholinergic-induced chorea in the treatment of focal dystonia |
